

PROMISING AGENTS AND NOVEL APPROACHES

Bentham Books

Heterocyclic Chemistry in Oncology: Promising Agents and Novel Approaches

Edited by

Smriti Dewangan

*Amity Institute of Pharmacy
Amity University Chhattisgarh
Raipur, Chhattisgarh, India*

Anchal Verma

*Department of Pharmacology
Shri Rawatpura Sarkar Institute of Pharmacy
Chhattisgarh Swami Vivekanand Technical University
Kumhari, Chhattisgarh
India*

&

Varsha Rawat

*Department of Pharmaceutics
Shri Rawatpura Sarkar Institute of Pharmacy
Chhattisgarh Swami Vivekanand Technical University
Kumhari, Chhattisgarh
India*

Heterocyclic Chemistry in Oncology: Promising Agents and Novel Approaches

Editors: Smriti Dewangan, Anchal Verma and Varsha Rawat

ISBN (Online): 979-8-89881-708-4

ISBN (Print): 979-8-89881-709-1

ISBN (Paperback): 979-8-89881-710-7

© 2026, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore,
in collaboration with Eureka Conferences, USA. All Rights Reserved.

First published in 2026.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.org.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

No. 9 Raffles Place

Office No. 26-01

Singapore 048619

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

FOREWORD	i
PREFACE	ii
LIST OF CONTRIBUTORS	iii
CHAPTER 1 FUNDAMENTALS AND APPLICATIONS OF HETEROCYCLIC CHEMISTRY IN DRUG DISCOVERY	1
<i>Richa Shrivastava, Anchal Verma, Varsha Rawat and Smriti Dewangan</i>	
INTRODUCTION	1
ROLE OF HETEROATOMS IN HETEROCYCLIC COMPOUNDS	2
Heterocycles Containing Nitrogen (N) (Pyridine, Pyrrole)	2
Oxygen (O) Containing Heterocycles (Furan, Tetrahydrofuran, Oxazole)	3
Sulfur (S) Containing Heterocycles (Thiophene, Thiazole, Tetrahydrothiophene)	3
BIOLOGICAL IMPACT OF HETEROATOMS	4
MECHANISTIC INFLUENCE ON BIOLOGICAL ACTIVITY [19]	5
Hydrogen Bonding and Molecular Recognition	5
Electronic Effects	5
Acid–Base Properties and Ionization	5
Lipophilicity and Membrane Permeation	5
Metal Coordination in Metalloenzymes	5
NOMENCLATURE OF HETEROCYCLES	5
BASIC PRINCIPLES OF HETEROCYCLIC CHEMISTRY	6
Structure and Ring Types	6
Electronic Properties	6
Aromaticity	6
Reactivity	6
Electronic and Steric Effects in Heterocycles	7
<i>Electronic Effects</i>	7
<i>Substituent Effects (EWG/EDG)</i>	7
Ring Size and Strain	8
Substituent Bulk	8
Tautomerism & Conformational Effects	8
Biological and Pharmaceutical Relevance	8
SYNTHETIC METHODS OF HETEROCYCLIC COMPOUNDS	9
General Strategies	9
Named Reactions in Heterocyclic Synthesis	9
Example:	10
Multi-component and Green Synthetic Approaches	10
Use of Catalysts and Solvents	10
HETEROCYCLIC COMPOUNDS IN THE CANCER TREATMENT	11
Case Study Example:	11
CLINICAL APPLICATIONS OF HETEROCYCLIC COMPOUNDS IN CANCER TREATMENT	12
DNA Interaction and Damage	12
EXAMPLES OF COMMON HETEROCYCLES USED FOR CANCER TREATMENT	12
5-Fluorouracil (5-FU)	13
Imatinib (Gleevec)	13
Paclitaxel (Taxol)	13
Cisplatin	13
Doxorubicin or Adriamycin	13

Epirubicin	14
Vincristine	14
Methotrexate	14
Challenges and Drug Resistance	14
Adverse Effects of Heterocyclic Agents	14
SYNTHETIC HETEROCYCLES IN TARGETED THERAPY	15
FUTURE PROSPECTS	15
CONCLUSION	15
ACKNOWLEDGEMENT	16
REFERENCES	16
CHAPTER 2 HETEROCYCLIC COMPOUNDS AS ANTICANCER AGENTS	22
<i>Biswa Mohan Sahoo, Suchismita Acharya, Subas Chandra Dinda, Dipthi Shree and Anchal Verma</i>	
INTRODUCTION	23
KEY FEATURES OF HETEROCYCLIC COMPOUNDS AS ANTI-CANCER AGENTS ...	24
GENERAL MECHANISMS OF ACTION OF HETEROCYCLIC COMPOUNDS AS ANTICANCER AGENTS	25
HETEROCYCLIC COMPOUNDS WITH ANTICANCER ACTIVITY	26
Purines and Pyrimidines as Anticancer Agents	27
Pyridines as anticancer agents	29
Quinoline Derivatives as Anticancer Agents	30
Quinazolines as anticancer agents	32
Indoles as Anticancer Agents	33
Indazole as an Anticancer Agent	34
Oxetane as an Anticancer Agent	35
Thiazoles as Anticancer Agents	35
Oxazoles as Anticancer Agents	36
Imidazoles as Anticancer Agents	37
Triazoles as Anticancer Agents	38
Benzimidazoles as Anticancer Agents	39
STRUCTURE-ACTIVITY RELATIONSHIP (SAR) STUDY	40
CHALLENGES AND FUTURE DIRECTIONS	40
CONCLUSION	41
REFERENCES	41
CHAPTER 3 TARGETING CANCER-SPECIFIC PATHWAYS WITH HETEROCYCLES	48
<i>Deepa Iyer, Sonika Prajapati and Nimisha Jain</i>	
INTRODUCTION	49
Overview of Cancer and Its Molecular Pathways	49
Role of Small Molecules in Cancer Therapy	50
Importance of Heterocyclic Compounds in Drug Discovery	50
INHIBITION OF ONCOGENIC SIGNALING PATHWAYS	50
Phosphatidylinositol-3-Kinase/Protein Kinase B/ Mammalian target of Rapamycin (PI3K/AKT/mTOR) Pathway	51
Mitogen-Activated Protein Kinase/ Extracellular Signal-Regulated Kinase (MAPK/ERK) Pathway	52
Epidermal Growth Factor Receptor (EGFR) Pathway	52
Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B cells (NF κ B) Pathway	53
Wingless-Related Integration Site and β -Catenin (Wnt/ β -Catenin) Pathway	53
Janus Kinase/ Signal Transducer and Activator of Transcription (JAK/STAT) Pathway	53
Hedgehog (Hh) Signaling Pathway	54

Apoptosis	54
Angiogenesis	54
TARGETING DNA REPAIR MECHANISMS	55
Poly (ADP-ribose) Polymerase (PARP) Inhibition	56
Homologous Recombination (HR) Inhibition	56
DNA Double-Strand Break Repair Pathway (NHEJ) Inhibition	56
Mismatch Repair (MMR) Inhibition	57
Inhibition of DNA Replication Stress Response	57
MODULATION OF EPIGENETIC ALTERATION	58
DNA Methylation Modulation	58
Histone Modification Modulation	59
Chromatin Remodeling	59
Non-Coding RNA (ncRNA) Modulation	60
Long Non-Coding RNA (lncRNA) Modulation	61
CONCLUSION	61
CONFLICT OF INTEREST	62
ACKNOWLEDGEMENT	62
REFERENCES	62
 CHAPTER 4 DESIGN AND DEVELOPMENT OF NOVEL HETEROCYCLE ANTICANCER AGENTS	 70
<i>Lokkanya Dewangan, Anju Daharia and Alok Singh Thakur</i>	
INTRODUCTION	70
CHEMISTRY OF HETEROCYCLIC SCAFFOLDS IN ANTICANCER DRUG DESIGN	72
Classification of Heterocyclic Compounds	72
Common Heterocyclic Scaffolds in FDA-approved Anticancer Drugs	73
Structural Diversity and Its Implications for Biological Activity	77
MECHANISMS OF ACTION OF HETEROCYCLIC ANTICANCER AGENTS	78
DNA Interactions	78
Enzyme Inhibition	79
Apoptosis Induction	79
Anti-angiogenesis and Metastasis Inhibition	79
RATIONAL DESIGN OF HETEROCYCLIC ANTICANCER AGENTS	82
SYNTHETIC APPROACHES FOR HETEROCYCLIC ANTICANCER AGENTS	84
Conventional Methods	84
Green Chemistry Approaches	85
PRECLINICAL AND CLINICAL EVALUATION OF HETEROCYCLIC ANTICANCER DRUGS	87
<i>In Vitro</i> Studies	88
<i>In Vivo</i> Models: Xenografts and Genetically Engineered Mouse Models	89
Clinical Trials and FDA Approvals	89
CHALLENGES AND FUTURE PERSPECTIVES	90
Drug Resistance and Overcoming Limitations	90
Role of Nanotechnology in Heterocycle-based Cancer Therapy	90
AI and Machine Learning in Drug Discovery	90
Future Trends in Personalized Medicine and Targeted Therapies	91
CONCLUSION	91
ACKNOWLEDGEMENT	91
REFERENCES	92

CHAPTER 5 CLINICAL APPLICATIONS AND CASE STUDIES	98
<i>Venu Anand Das Vaishnav, Nishant Sudhir Jain, Vaibhav Maturkar and Chhatrapal Patel</i>	
INTRODUCTION	98
Overview of Clinical Trials	98
Role of Clinical Trials	99
CASE STUDIES OF HETEROCYCLIC COMPOUNDS IN CLINICAL PRACTICE	100
Case Study-1: Pyridine Derivative in Breast Cancer	100
<i>Anti-Breast Cancer Activity Evaluation of Novel 3-Cyanopyridine Derivatives as PIM-1 Inhibitors</i>	100
<i>Recent Studies of Pyridine Derivatives as an Anticancer Agent</i>	102
Case Study-2: Purine Analogues in Leukemia Treatment	102
<i>Purine Nucleoside Analogues</i>	102
<i>Purine Nucleoside Analogs as Immunosuppressive and Antineoplastic Agents: Mechanism of Action and Clinical Activity</i>	103
Case Study-3: Indole-Based Compounds in Prostate Cancer	103
<i>Plant Foods, Antioxidants, and Prostate Cancer Risk: Findings from Case-Control Studies in Canada</i>	103
<i>Novel Naftopidil-related Derivatives and their Biological Effects as Alpha1-adrenoceptor Antagonists and Antiproliferative Agents</i>	104
Case Study 4-A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy, and Tumor Treating Fields	104
Case Study 5- Hesperetin Relieves Cisplatin-induced Acute Kidney Injury by Mitigating Oxidative Stress, Inflammation, and Apoptosis	105
CHALLENGES AND FUTURE DIRECTIONS IN CLINICAL TRANSLATION	106
Drug Resistance Mechanism in Cancer Therapy	106
Current Perspectives on Immune Checkpoint Therapy	107
Antibody-drug Conjugates in Cancer Therapy	107
TRANSLATIONAL FRONTIERS ON CANCER NEUROSCIENCE	108
CONCLUSION	108
ACKNOWLEDGEMENT	108
REFERENCES	109
CHAPTER 6 NATURAL PRODUCTS AND HETEROCYCLES IN CANCER THERAPY	114
<i>Vidya Kakad and Tripti Sharma</i>	
INTRODUCTION	114
Heterocyclic Compounds as Anticancer Agents	116
Molecular Mechanisms of Natural Heterocyclic Scaffolds as Anticancer Agents	117
NATURALLY OCCURRING HETEROCYCLIC ANTICANCER COMPOUNDS	119
Nitrogen-Based Heterocycles	120
Oxygen-based Heterocycle	122
Sulphur-based Heterocycle	123
FDA-APPROVED NATURAL HETEROCYCLIC COMPOUNDS FOR CANCER	
TREATMENT	124
CONCLUSION	130
ACKNOWLEDGEMENT	131
REFERENCES	131
CHAPTER 7 HETEROCYCLES AND CANCER BIOMARKERS	136
<i>Ashish Majumdar, S Prakash Rao, Surendra Kumar Saraf and Jitendra Patel</i>	
INTRODUCTION	137
Overview of Cancer Biomarkers	137
Role of Heterocyclic Compounds in Modern Oncology	137

Objectives and Scope of the Chapter	139
<i>Grasping the Essence of Cancer Biomarkers</i>	139
<i>Assessing the Healing Possibilities</i>	139
<i>Navigating Challenges and Exploring Fresh Concepts</i>	139
UNDERSTANDING CANCER BIOMARKERS: THEIR TYPES AND IMPORTANCE	139
Genetic Indicators: Changes and Cancer Genes	140
Epigenetic Markers: Methylation and Histone Modifications	140
Protein-Based Biomarkers: Enzymes, Receptors, and Cytokines	141
Emerging Biomarkers: Circulating Tumor DNA and Exosomes	141
HETEROCYCLIC COMPOUNDS: A VERSATILE FRAMEWORK	142
Structural Features and Synthetic Methods	143
Pharmacokinetics and Pharmacodynamics of Heterocycles	143
Advantages in Targeting Cancer Biomarkers	144
HETEROCYCLES IN THE DETECTION AND DIAGNOSIS OF CANCER	145
Fluorescent Heterocyclic Probes for Biomarker Imaging	145
Applications in Liquid Biopsy and Diagnostic Tools	146
Case Studies: Diagnostic Agents Based on Heterocycles	148
HETEROCYCLES IN TARGETED THERAPY OF CANCER	149
Inhibition of Biomarker-Driven Pathways	149
Heterocyclic Drugs Modulating Specific Biomarkers	150
Case Studies: Exemplary Outcomes and Clinical Implementations	151
<i>Case Study 1: Imatinib and Chronic Myeloid Leukemia</i>	151
<i>Case Study 2: Erlotinib in Lung Cancer</i>	151
<i>Case Study 3: Olaparib in Cancers with BRCA Mutations</i>	151
<i>Case Study 4: Sunitinib in Kidney Cancer</i>	152
<i>Case Study 5: Vorinostat in T-Cell Lymphoma</i>	152
CHALLENGES AND LIMITATIONS	153
Stability and Bioavailability Issues	153
<i>Chemical Stability</i>	153
<i>Challenges in Bioavailability</i>	153
<i>Off-Target Effects</i>	154
Approaches to Improve Healing Effectiveness	154
<i>Thoughtful Drug Creation</i>	155
<i>Focused Medication Distribution</i>	155
<i>Navigating Challenges in the Tumor Microenvironment</i>	155
<i>Clinical Execution</i>	155
FUTURE DIRECTIONS	156
Integrating Heterocyclic Chemistry with Biomarker Research	156
<i>Enhancing Target-Specific Drug Design</i>	156
<i>Collaboration with Molecular Biology</i>	157
<i>Case Studies in Clinical Translation</i>	157
Role of Machine Learning in Heterocyclic Drug Development	157
<i>Accelerating Drug Discovery</i>	157
<i>Optimizing Synthesis Pathways</i>	157
<i>Personalized Medicine Applications</i>	158
Innovations in Cancer Biomarker Identification	158
<i>Advances in Liquid Biopsy Techniques</i>	158
<i>Single-Cell Analysis and Heterocyclic Probes</i>	158
<i>High-Throughput Screening Platforms</i>	158
<i>CRISPR-Cas9 and Heterocycles</i>	158
Future Outlook	159

CONCLUSION	159
CONFLICT OF INTEREST	160
ACKNOWLEDGEMENT	160
REFERENCES	160
CHAPTER 8 DRUG RESISTANCE AND HETEROCYCLIC COMPOUNDS	169
<i>Rohini Armo, Deepika Singh, Rishi Paliwal and Anand Kumar</i>	
INTRODUCTION	169
ROLE OF HETEROCYCLIC COMPOUNDS IN OVERCOMING DRUG RESISTANCE	176
Inhibition of Resistance Mechanisms	176
Targeting Mutated Proteins	177
Combination Therapy	177
Prodrug Design	177
Nanocarrier Systems	177
Epigenetic Modulation	177
Antimicrobial Resistance Combat	178
Drug Repurposing	178
STRATEGIES TO OVERCOME DRUG RESISTANCE USING (N, O, S)	
HETEROCYCLIC COMPOUNDS	178
Nitrogen Heterocyclic Compounds (NHCs)	178
Oxygen Heterocyclic Compounds (OHCs)	180
Sulfur Heterocyclic Compounds (SHCs)	180
FUTURE DIRECTIONS IN COMBATING DRUG RESISTANCE	181
CONCLUSION	183
ACKNOWLEDGEMENT	183
REFERENCES	183
CHAPTER 9 TOXICITY AND SAFETY ASSESSMENT OF HETEROCYCLIC	
ANTICANCER AGENTS	191
<i>Gaurav Kesharwani, Ankit Mishra, Pranali Mishra and Smriti Dewangan</i>	
INTRODUCTION	191
TOXICITY MECHANISMS OF HETEROCYCLIC ANTICANCER AGENTS	193
Toxicity Mechanisms of HAA: DNA Damage and Genotoxicity	194
Toxicity Mechanisms of HAA: Oxidative Stress and Mitochondrial Toxicity	194
Toxicity Mechanisms of HAA: Off-Target Interactions and Immune System Effects	195
Toxicity Mechanisms of HAA: Metabolic Toxicity and Organ-Specific Adverse Effects	195
TOXICITY ASSESSMENT	196
Toxicity Assessment of HAA through In-Vitro Cytotoxicity Assays	196
Preclinical Toxicity Studies	197
<i>In vivo</i> Animal Models for Toxicity Evaluation	197
Pharmacokinetics and Dose-response Relationship	198
Biomarkers for Toxicity Prediction	198
Clinical Toxicity Assessment	199
<i>Phase I–III Clinical Trials and Safety Endpoints</i>	199
<i>Adverse Drug Reactions (ADR) Reporting and Management</i>	200
<i>Dose-limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD)</i>	201
Mechanism-Based Toxicity	201
SAFETY ASSESSMENT	202
Pharmacokinetics and ADME Studies	203
Predictive Toxicology	204
Regulatory Guidelines	204
STRATEGIES TO MITIGATE TOXICITY	205

EMERGING TRENDS AND FUTURE DIRECTIONS	206
CONCLUSION	208
ACKNOWLEDGEMENT	208
REFERENCES	208
CHAPTER 10 HETEROCYCLE IN CANCER PREVENTION AND CHEMOPREVENTION	215
<i>Anup Kumar Patra, Aruna Ghose, Jasaswi Ray, Rajashree Mohanty and Shakti Ketan Prusty</i>	
INTRODUCTION	216
Overview of Cancer and Chemoprevention	216
Importance of Heterocycles in Medicinal Chemistry	217
Historical Background of Heterocyclic Compounds in Cancer Therapy	218
BIOLOGICAL SIGNIFICANCE OF NITROGEN, OXYGEN, AND SULFUR-CONTAINING HETEROCYCLES	219
Nitrogen-Containing Heterocycles	219
Oxygen-Containing Heterocycles	219
Sulfur-Containing Heterocycles	219
MECHANISMS OF CHEMOPREVENTION	220
Inhibition of Carcinogen Activation	220
<i>Mechanisms of Carcinogen Activation</i>	220
Antioxidant and Anti-inflammatory Activity	220
<i>Antioxidant Activity</i>	221
<i>Anti-Inflammatory Activity</i>	221
Modulation of Signal Transduction Pathways	221
<i>Key Signaling Pathways and Their Modulation</i>	222
Induction of Apoptosis and Cell Cycle Arrest	222
Inhibition of Angiogenesis and Metastasis	223
<i>Angiogenesis: The Formation of New Blood Vessels</i>	223
<i>Metastasis: The Spread of Cancer Cells</i>	223
NATURAL HETEROCYCLIC COMPOUNDS IN CANCER PREVENTION	224
Alkaloids (e.g., Vincristine, Camptothecin)	224
<i>Vincristine</i>	224
<i>Camptothecin</i>	225
Flavonoids and Isoflavones	225
Indoles (e.g., Indole-3-carbinol)	225
Coumarins and Quinolones	226
SYNTHETIC HETEROCYCLIC COMPOUNDS WITH CHEMOPREVENTIVE POTENTIAL	226
Pyridines, Pyrazoles, and Triazoles	226
Imidazoles and Benzimidazoles	227
Thiazoles and Oxazoles	227
Quinazolines and Isoquinolines	228
Thiadiazines and Thiophenes	228
TARGET-SPECIFIC HETEROCYCLES IN CANCER CHEMOPREVENTION	228
COX-2 Inhibitors (e.g., Celecoxib Analogs)	228
<i>Mechanism of Action</i>	229
Tyrosine Kinase Inhibitors	229
<i>Mechanism of Action</i>	229
HDAC Inhibitors	230
PI3K/mTOR Pathway Modulators	230
GREEN SYNTHESIS APPROACHES FOR HETEROCYCLES	231

Eco-friendly Synthesis of Bioactive Heterocycles	231
Use of Green Catalysts and Green Solvents	232
Case Studies in Green Synthesis of Anticancer Heterocycles	232
<i>Green Synthesis of Benzothiazole Derivatives</i>	232
<i>Eco-Friendly Synthesis of Isoquinoline Derivatives Using Ionic Liquids</i>	233
<i>Catalytic Synthesis of Pyrazole Derivatives Using Biocatalysts</i>	233
COMPUTATIONAL AND AI-BASED APPROACHES FOR DESIGNING	
HETEROCYCLE CHEMIOPREVENTIVE DRUGS	233
Molecular Docking and QSAR Studies	233
ADMET Prediction of Heterocyclic Leads	234
Machine Learning in Chemopreventive Drug Discovery	234
CLINICAL AND PRECLINICAL STUDIES	234
Case Examples of Heterocycles in Clinical Trials	234
Preclinical Models for Chemopreventive Evaluation	235
Safety, Toxicity, and Pharmacokinetics	235
CHALLENGES IN DESIGNING HETEROCYCLES FOR CHEMOPRE-VENTION	236
Resistance Development	236
Selectivity Issues	237
Strategies for Improving Efficacy and Safety	237
FUTURE TRENDS IN HETEROCYCLE-BASED CHEMOPREVENTION	237
Multi-Targeted Heterocyclic Agents	237
Integration of Artificial Intelligence (AI) and Machine Learning (ML)	238
Natural Product-Inspired Heterocycles	238
Green and Sustainable Synthesis	238
Personalized Chemoprevention	238
Nanotechnology Integration	238
CONCLUSION	238
ACKNOWLEDGEMENT	239
REFERENCES	239
CHAPTER 11 MULTIDISCIPLINARY APPROACHES TO HETEROCYCLIC ONCOLOGY	
RESEARCH	246
<i>Vinita Gotti, Anchal Verma and Rohini Armo</i>	
INTRODUCTION	246
Integration of Chemistry, Biology, and Medicine in Heterocycle Research	248
Chemistry of Heterocycle compounds for Oncology research	248
Biology of Heterocyclic Compounds for Oncology Research	250
Medicine of Heterocyclic Compounds for Oncology Research	251
MULTIDISCIPLINARY CONTRIBUTIONS TO HETEROCYCLIC ONCOLOGY	
RESEARCH	252
Medicinal Chemistry	252
Pharmacology	253
Computational Chemistry and Artificial Intelligence	253
Green Chemistry	253
Cancer Biology	253
Nanotechnology	253
Clinical Science	254
CASE STUDIES DEMONSTRATING SUCCESSFUL MULTIDISCIPLINARY	
APPROACH	254
Case Study 1: Discovery of Imatinib (Gleevec)	255
Case Study 2: Green Synthesis of Thiazole Derivatives	255

Case Study 3: Heterocycles in Organic Electronics (OLEDs)	256
Case Study 4: Discovery of Osimertinib – A Breakthrough in Targeted Lung Cancer Therapy	256
Case Study 5: PARP Inhibitors and Phthalazinones – Targeting DNA Repair in Cancer	257
Case Study 6: Heterocyclic PROTACs – Targeted Protein Degradation in Cancer Therapy	257
FUTURE PERSPECTIVES ON INTERDISCIPLINARY RESEARCH IN HETEROCYCLIC ONCOLOGY	258
CONCLUSION	259
ACKNOWLEDGEMENT	260
REFERENCES	260
CHAPTER 12 EMERGING TRENDS AND NOVEL APPROACHES	268
<i>Gunjan Kalyani, Disha Kesharwani, Monika Bhairam and Sandhya Mishra</i>	
INTRODUCTION	269
Nitrogen-based Heterocycles	271
Oxygen-based Heterocycles	272
Sulphur-based Heterocycles	274
NOVEL APPROACHES	276
ADVANCES IN DRUG DELIVERY SYSTEMS	277
Development of Cytotoxic Heterocyclic Nucleoside Analogues	278
Heterocyclic Nanoformulations for Targeted Anti-tumor Therapy	279
INTEGRATION OF HETEROCYCLES IN MULTIMODAL THERAPEUTIC STRATEGIES	280
Thiazolidinone in Cancer Therapy	280
Modified 5-FU and its Advances	281
Quinazoline Derivatives in Cancer Treatment	281
HETEROCYCLES IN CANCER IMMUNOTHERAPY	281
FUTURE DIRECTIONS	283
CONCLUSION	283
ACKNOWLEDGEMENT	284
REFERENCES	284
SUBJECT INDEX	292

FOREWORD

Cancer remains one of the most formidable challenges in modern medicine, prompting continuous research into new therapeutic agents. Among the various approaches to drug discovery, heterocyclic chemistry has emerged as a key component in the development of effective and selective anticancer drugs. The book *Heterocyclic Chemistry in Oncology: Promising Agents and Novel Approaches* is a valuable and timely contribution to this rapidly evolving field, offering in-depth insights into the significance of heterocyclic scaffolds in anticancer drug development.

Authored by renowned researchers and scholars, the book provides a comprehensive review of heterocyclic compounds, highlighting their structural diversity and mechanistic roles in targeting diverse cancer pathways. Its significance lies not only in its academic rigor but also in its ability to bridge fundamental heterocyclic chemistry with translational oncology. By integrating medicinal chemistry, computational modeling, and innovative drug development strategies, the book serves as an excellent resource for researchers, academicians, and pharmaceutical scientists seeking to advance oncology therapeutics.

As a professor specializing in pharmaceutical and medicinal chemistry, I consider this book to be an engaging and essential resource for those aiming to harness the potential of heterocyclic chemistry in cancer treatment. I commend the authors for their outstanding efforts and am confident that this work will stimulate further research and breakthroughs in the field of oncology.

Gregory Smith
Department of Chemistry
University of Cape Town
Cape Town, Western Cape
South Africa

PREFACE

The intersection of heterocyclic chemistry and oncology represents one of the most dynamic and promising areas in contemporary medicinal chemistry. This book, “Heterocyclic Chemistry in Oncology: Promising Agents and Novel Approaches”, is the culmination of extensive research and exploration into the vital role that heterocyclic compounds play in the development of novel cancer therapies. As the complexity of cancer continues to challenge the scientific community, it is the versatility and potency of heterocycles that offer a beacon of hope for more effective, targeted treatments. In preparing this work, I sought to provide a comprehensive overview of the most significant advancements in this field, emphasizing both the chemical ingenuity and the therapeutic potential of heterocyclic compounds. The chapters are designed to guide the reader through the intricate landscape of heterocyclic chemistry, highlighting key structural motifs and their applications in targeting diverse oncogenic pathways.

This book is intended for researchers, students, and professionals in medicinal chemistry, oncology, and related disciplines who are keen to explore the frontiers of drug discovery. It is my hope that the insights presented here will inspire further innovation and collaboration, ultimately leading to breakthroughs that may change the course of cancer treatment.

I would like to express my gratitude to the many scientists and colleagues whose work has informed and enriched this book. Their dedication to advancing our understanding of cancer and improving patient outcomes through chemical innovation is truly inspiring. This book is dedicated to them and to the patients whose lives depend on our collective efforts to overcome cancer.

Smriti Dewangan

Amity Institute of Pharmacy
Amity University Chhattisgarh
Raipur, Chhattisgarh
India

Anchal Verma

Department of Pharmacology
Shri Rawatpura Sarkar Institute of Pharmacy
Chhattisgarh Swami Vivekanand Technical University
Kumhari, Chhattisgarh, India

&

Varsha Rawat

Department of Pharmaceutics
Shri Rawatpura Sarkar Institute of Pharmacy
Chhattisgarh Swami Vivekanand Technical University
Kumhari, Chhattisgarh, India

List of Contributors

Alok Singh Thakur	Department of Chemistry, Shri Shankaracharya Institute of Pharmaceutical Sciences and Research, Shri Shankaracharya Professional University, Bhilai, Chhattisgarh, India
Anchal Verma	Department of Pharmacology, Shri Rawatpura Sarkar Institute of Pharmacy, Chhattisgarh Swami Vivekanand Technical University, Kumhari, Chhattisgarh, India
Anand Kumar	University Department of Pharmacy, Santgahira Guru University, Ambikapur, Chhattisgarh, India
Ankit Mishra	Faculty of Pharmacy, VNS Group of Institutions, Rajiv Gandhi Proudhyogiki Vishwavidyalaya, Bhopal, Madhya Pradesh, India
Anju Daharia	Department of Chemistry, Kamla Institute of Pharmaceutical Sciences, Shri Shankaracharya Professional University, Bhilai, Chhattisgarh, India
Anup Kumar Patra	Department of Pharmaceutical Analysis, College of Pharmaceutical Sciences, Biju Patnaik University of Technology, Puri, Odisha, India
Aruna Ghose	Department of Pharmacology, School of Pharmaceutical Sciences, Siksha'o' Anushandhan Deemed to be University, Bhubaneswar, Odisha, India
Ashish Majumdar	Department of Pharmaceutical Sciences, Columbia Institute of Pharmacy, Chhattisgarh Swami Vivekanand Technical University, Raipur, Chhattisgarh, India
Biswa Mohan Sahoo	School of Pharmacy and Life Sciences, Centurion University of Technology & Management, Jatni, Odisha, India
Chhatrapal Patel	Department of Pharmacy, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh, India
Deepa Iyer	M.P. Council of Science and Technology, Vigyan Bhawan, Bhopal, Madhya Pradesh, India
Dipthi Shree	Department of Pharmaceutics, Roland Institute of Pharmaceutical Sciences, Berhampur, Odisha, India
Disha Kesharwani	Columbia Institute of Pharmacy, Chhattisgarh Swami Vivekanand Technical University, Raipur, Chhattisgarh, India
Deepika Singh	Nanomedicine and Bioengineering Research Laboratory, Department of Pharmacy, Indira Gandhi National tribal University, Amarkantak, Madhya Pradesh, India
Gaurav Kesharwani	Faculty of Pharmacy, VNS Group of Institutions, Rajiv Gandhi Proudhyogiki Vishwavidyalaya, Bhopal, Madhya Pradesh, India
Gunjan Kalyani	Columbia Institute of Pharmacy, Chhattisgarh Swami Vivekanand Technical University, Raipur, Chhattisgarh, India
Jasaswi Ray	Department of Pharmaceutical Analysis, College of Pharmaceutical Sciences, Biju Patnaik University of Technology, Puri, Odisha, India

Jitendra Patel	Department of Pharmacognosy, Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education (Deemed to be University), Wardha, Maharashtra, India
Lokkanya Dewangan	Department of Chemistry, Shri Shankaracharya Institute of Pharmaceutical Sciences and Research, Shri Shankaracharya Professional University, Bhilai, Chhattisgarh, India
Monika Bhairam	Columbia Institute of Pharmacy, Chhattisgarh Swami Vivekanand Technical University, Raipur, Chhattisgarh, India
Nimisha Jain	Institute of Pharmacy, Rabindranath Tagore University, Bhojpur, Madhya Pradesh, India
Nishant Sudhir Jain	Department of Pharmacy, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh, India
Pranali Mishra	Swami Vivekanand College of Pharmacy, Rajiv Gandhi Proudhyogiki Vishwavidyalaya, Bhopal, Madhya Pradesh, India
Rajashree Mohanty	Department of Pharmaceutical Analysis, College of Pharmaceutical Sciences, Biju Patnaik University of Technology, Puri, Odisha, India
Richa Shrivastava	Department of Chemistry, Govt. Naveen Girls College, Sant Gahira Guru University, Baikunthpur, Chhattisgarh, India
Rohini Armo	Department of Pharmachemistry, Shri Rawatpura Sarkar Institute of Pharmacy, Chhattisgarh Swami Vivekanand Technical University, Kumhari, Chhattisgarh, India
Rishi Paliwal	Nanomedicine and Bioengineering Research Laboratory, Department of Pharmacy, Indira Gandhi National tribal University, Amarkantak, Madhya Pradesh, India
S Prakash Rao	Department of Pharmacognosy, Shri Rawatpura Sarkar Institute of Pharmacy, Chhattisgarh Swami Vivekanand Technical University, Kumhari, Chhattisgarh, India
Sandhya Mishra	Columbia Institute of Pharmacy, Chhattisgarh Swami Vivekanand Technical University, Raipur, Chhattisgarh, India
Shakti Ketan Prusty	Department of Pharmacology, School of Pharmaceutical Sciences, Siksha'o' Anushandhan Deemed to be University, Bhubaneswar, Odisha, India
Smriti Dewangan	Amity Institute of Pharmacy, Amity University Chhattisgarh, Raipur, Chhattisgarh, India
Sonika Prajapati	Institute of Pharmacy, Rabindranath Tagore University, Bhojpur, Madhya Pradesh, India
Suchismita Acharya	Department of Chemistry, School of Applied Sciences, Centurion University of Technology & Management, Jatni, Odisha, India
Subas Chandra Dinda	School of Pharmacy, The Neotia University, Jhinga, West Bengal, India
Surendra Kumar Saraf	Department of Pharmaceutical Sciences, Columbia Institute of Pharmacy, Chhattisgarh Swami Vivekanand Technical University, Raipur, Chhattisgarh, India

Tripti Sharma	Department of Pharmaceutical Chemistry, Bomaby College of Pharmacy, University of Mumbai, Mumbai, Maharashtra, India
Varsha Rawat	Department of Pharmaceutics, Shri Rawatpura Sarkar Institute of Pharmacy, Chhattisgarh Swami Vivekanand Technical University, Kumhari, Chhattisgarh, India
Vaibhav Maturkar	Department of Pharmacy, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh, India
Venu Anand Das Vaishnav	Department of Pharmacy, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh, India
Vidya Kakad	Faculty of Pharmacy, Chhatrapati Shivaji Maharaj University, Navi Mumbai, Maharashtra, India
Vinita Goti	Department of Pharmacology, Shri Rawatpura Sarkar Institute of Pharmacy, Chhattisgarh Swami Vivekanand Technical University, Kumhari, Chhattisgarh, India

CHAPTER 1**Fundamentals and Applications of Heterocyclic Chemistry in Drug Discovery****Richa Shrivastava¹, Anchal Verma², Varsha Rawat³ and Smriti Dewangan^{4,*}**¹ Department of Chemistry, Govt. Naveen Girls College, Sant Gahira Guru University, Baikunthpur, Chhattisgarh, India² Department of Pharmacology, Shri Rawatpura Sarkar Institute of Pharmacy, Chhattisgarh Swami Vivekanand Technical University, Kumhari, Chhattisgarh, India³ Department of Pharmaceutics, Shri Rawatpura Sarkar Institute of Pharmacy, Chhattisgarh Swami Vivekanand Technical University, Kumhari, Chhattisgarh, India⁴ Amity Institute of Pharmacy, Amity University Chhattisgarh, Raipur, Chhattisgarh, India

Abstract: Today's medicinal scientists focus on making anticancer drugs using heterocyclic chemistry. This chapter explains the essential concepts of heterocyclic chemistry, as well as how to synthesize, react, define aromatic compounds, and categorize important types of heterocyclic compounds. Much focus is given to certain five- or six-membered heterocycles that often show up in bioactive substances and have nitrogen, oxygen, and sulfur atoms, such as pyrroles, pyridines, imidazoles, and quinolines. In the chapter, researchers explore ways that heterocyclic frameworks are vital for the development of anticancer medications. In addition, how heterocyclic compounds interact with very important biological targets such as DNA, enzymes, and proteins involved in tumor development is also analyzed. This chapter points out that when heterocyclic chemistry links organic chemistry and medicine, it plays a key role in developing cancer treatments and discovering new drugs.

Keywords: Active molecules, Anticancer drugs, Aromatic groups, Building rings, Designing medicines, Fitting to DNA, Heterocyclic chemistry, Imidazole, Kinase inhibitors, Medicinal chemist, Organic synthesis, Pharmacophores, Pyridine, Quinolines.

INTRODUCTION

This particular branch of organic chemistry examines synthesizing, studying, and making use of heterocyclic compounds, cyclic molecules that typically contain

* Corresponding author Smriti Dewangan: Amity Institute of Pharmacy, Amity University Chhattisgarh, Raipur, Chhattisgarh, India; E-mail: smritidewangan88@gmail.com

nitrogen, oxygen, or sulfur along with carbon [1]. Heterocyclic chemistry is the area of science dedicated to cyclic groups that have at least one heteroatom (nitrogen, oxygen, or sulfur) present in the ring and to learning about the ways these compounds are made and used. Their presence in many actives, pharmaceuticals, agrochemicals, and natural products makes these compounds fundamentally necessary [2]. As part of organic chemistry, heterocyclic chemistry has grown and changed during a long and active history. Uric acid, an early naturally occurring heterocycle, was first identified in 1806. In 1832, chemicals separated from tobacco led to the finding that nicotine contains a pyridine ring and was first identified as an early marker of heterocycles [3]. In 1845, scientists identified furan in the distillate of pine tar and included it in the increasing collection of known heterocyclic compounds. Between the late 1800s and early 1900s, chemists took part in future developments by synthesising pyrrole, thiophene, and quinoline. At the start of the 20th century, heterocycles began being used more often, largely in the pharmaceutical field, which led to discoveries of sulfa drugs and penicillin that changed health care. In recent times, the area has grown dramatically, leading to the development of several thousand heterocycles for use in medicine, agriculture, and materials science. Since they differ in ring size, number of heteroatoms, and are aromatic, heterocyclic compounds are very diverse in structure and properties [4]. Because they are versatile and reactive, they are useful in drug discovery, material science, and biochemistry, greatly improving what we know and can do in these areas [5].

ROLE OF HETEROATOMS IN HETEROCYCLIC COMPOUNDS

What defines a heterocyclic compound is the presence of heteroatoms. The structure, reactions, and effects on living things of heterocycles are highly dependent on their electronic, steric, and bonding features [6].

Heterocycles Containing Nitrogen (N) (Pyridine, Pyrrole)

A single pair of electrons on nitrogen allows it to work as a Lewis base, so it is recognized as basic. Heterocyclic compounds such as pyridine and pyrrole have nitrogen that, depending on its role, can be more or less basic in the aromatic system [7]. The π -system in pyridine is not linked by nitrogen because its lone pair is above and below in the sp^2 orbital, so pyridine fails to be aromatic. Pyridine is more basic than some other bases due to its lone pair; protonation occurs with ease. Alternatively, in pyrrole, the nitrogen's lone pair is delocalized and adds two electrons to the aromatic structure, so it is vital to the molecule's aromaticity. As a result, the lone pair is not easily accessible for bonding, which means pyrrole is not as basic as it could be. Acknowledging its single pair of electrons and charge, there is a good chance that nitrogen will create hydrogen

bonds and act as an acceptor. It can, however, act as a donor when it has a hydrogen atom bonded. Nitrogen can react easily with other chemical substances and also strongly influence how molecules interact with each other [8, 9], shown in Table 1 and Fig. (1).




Fig. (1). Nitrogen-containing heterocycles.

Oxygen (O) Containing Heterocycles (Furan, Tetrahydrofuran, Oxazole)

An aromatic ring becomes more reactive, and its overall structure may weaken, because electronegative atoms such as oxygen take a lot of electrons from it [10]. A lone pair present on one of the oxygen atoms in cyclic alkenes reaches into the aromatic π -system and makes the system more stable by delocalization. High electronegativity in oxygen allows it to readily accept hydrogen bonds, raising the water solubility and reactivity of the compound [11, 12]. Shown in Table 1 and Fig. (2).

Table 1. Comparison between heteroatom properties.

Heteroatom	Electronegativity	Lone Pairs	Aromatic Role	Reactivity Tendency
Nitrogen	Medium (3.0)	1	Sometimes contributes	Basic, nucleophilic
Oxygen	High (3.5)	2	One pair in aromaticity	Electron-rich, polar
Sulfur	Low (2.5)	2	One pair in aromaticity	Polarizable, less reactive




Fig. (2). Oxygen-containing heterocycles.

Sulfur (S) Containing Heterocycles (Thiophene, Thiazole, Tetrahydrothiophene)

Compared to oxygen, sulfur is more able to 'part with' electrons and so stabilizes positive charges by dispensing electron density [13]. Because of this, the electron activity of molecules with sulfur [14] in the aromatic rings tends to be less imposing than it is in rings with oxygen. Much like furan, a lone pair of sulfur participates in the aromatic cloud and, as a result, the molecule remains aromatic

Heterocyclic Compounds as Anticancer Agents

Biswa Mohan Sahoo^{1,*}, Suchismita Acharya², Subas Chandra Dinda³, Dipthi Shree⁴ and Anchal Verma⁵

¹ School of Pharmacy and Life Sciences, Centurion University of Technology & Management, Jatni, Odisha, India

² Department of Chemistry, School of Applied Sciences, Centurion University of Technology & Management, Jatni, Odisha, India

³ School of Pharmacy, The Neotia University, Jhinga, West Bengal, India

⁴ Department of Pharmaceutics, Roland Institute of Pharmaceutical Sciences, Berhampur, Odisha, India

⁵ Department of Pharmacology, Shri Rawatpura Sarkar Institute of Pharmacy, Chhattisgarh Swami Vivekanand Technical University, Kumhari, Chhattisgarh, India

Abstract: Cancer is one of the most serious healthcare issues in the world. Several anticancer medications are currently available on the market; however, they are either ineffective or have poor safety, with numerous side effects and resistance. As a result, there is an urgent need to produce safer and more targeted anticancer agents. Therefore, heterocyclic compounds play a vital role in developing anticancer agents due to their unique physicochemical properties and diverse biological activities. These compounds also exhibit significant effects by improving the pharmacokinetics and pharmacodynamics properties of anticancer drugs due to the augmentation of lipophilicity, polarity, or physicochemical features. They target specific genes, enzymes, and receptors associated with cancer. Heterocyclic compounds are integral to the ongoing research to fight against cancer, with their unique structures offering a pathway to innovative treatments. The ongoing research focuses on developing novel heterocyclic compounds with improved efficacy and reduced side effects. Investigating the potential of heterocycles in combination therapies can overcome drug resistance. Several clinically approved drugs contain heterocyclic structures, including Methotrexate, Vincristine, Vinblastine, Doxorubicin, Daunorubicin, and 5-Fluorouracil. Continued research and development in this area holds promise for more effective cancer therapies in the future.

Keywords: Activate, Angiogenesis, Cancer, DNA, Drug, Druggable, Fluorouracil, Hallmarks, Heterocycle, Inhibition, Invasion, Methotrexate, Mutation, Neoplastic, Proliferation, Side-effects, Treatment, Triggered, Uracil, Vincristine.

* Corresponding author **Biswa Mohan Sahoo**: School of Pharmacy and Life Sciences, Centurion University of Technology & Management, Jatni, Odisha, India; E-mail: drbiswamohansahoo@gmail.com

INTRODUCTION

Cancer is identified as a major public health burden in current circumstances around the globe. It is considered a significant contributor to mortality and morbidity worldwide [1]. Data indicate a consistent rise in cancer cases, with projections suggesting that by 2030, the global total will reach approximately 21 million cases. The World Health Organization (WHO) suggests that new cancer cases have grown over the last 20 years. Cancer encompasses a range of diseases characterized by the uncontrolled proliferation of abnormal cells within the body, which can metastasize to other regions [2, 3]. Cancer comprises three stages: initiation, promotion/progression, and metastasis. At the initiation stage, a mutation arises in the genetic components of the cells, resulting in the transformation of normal cells into malignant ones. In the progression stage, neoplastic transformation occurs, resulting in cell proliferation (Fig. 1). Finally, metastasis involves spreading cancer cells throughout the body [4 - 6].




Fig. (1). Development of cancer cells.

Cancer is caused by various factors, including environmental influences (radiation, smoking, chewing tobacco, pollution, chemicals, and infectious agents) and internal factors (genetic mutations, immune system, and hormonal disorders) [7, 8]. The ability of cancer to infiltrate and disseminate to neighboring tissue is one of its characteristics. Maintaining proliferative signals, avoiding growth suppressors, preventing cell death, permitting replicative immortality, avoiding immune destruction, starting angiogenesis, and triggering invasion and metastasis are some of the characteristics of cancer (Fig. 2) [9, 10].




Fig. (2). Hallmarks of cancer.

Various types of cancer can develop in several parts of the human body, such as the lung, liver, ovary, colon, rectum, prostate, breast, thyroid, and pancreas. The FDA has approved several anti-cancer agents, which are used therapeutically to treat various cancer types [11]. Chemo-resistance, severe toxicity, and metastasis are the main challenges in cancer treatment [12]. So, heterocyclic compounds play a vital role in developing anticancer drugs that can reduce these problems and treat cancer effectively. Because of their structural and chemical diversity, these molecules are a key focus for anticancer research and drug development. These compounds play a vital role in medicinal chemistry due to their diverse structural and functional properties, making them privileged scaffolds for drug development, including anticancer agents [13, 14].

KEY FEATURES OF HETEROCYCLIC COMPOUNDS AS ANTI-CANCER AGENTS

The key features of heterocyclic compounds as anti-cancer agents include structural versatility, interaction with biological targets, and drug-like properties. While considering structural versatility, heterocyclic rings provide a platform for

CHAPTER 3

Targeting Cancer-Specific Pathways with Heterocycles

Deepa Iyer¹, Sonika Prajapati² and Nimisha Jain^{2,*}

¹ M.P. Council of Science and Technology, Vigyan Bhawan, Bhopal, Madhya Pradesh, India

² Institute of Pharmacy, Rabindranath Tagore University, Bhojpur, Madhya Pradesh, India

Abstract: Cancer is a complex and multifactorial disease characterized by uncontrolled cell growth, invasion, and metastasis. Despite significant advances in cancer research, the enhancement of effective and targeted therapies remains a major challenge. The development of effective anticancer therapies requires a deep understanding of molecular mechanisms underlying cancer progression. Heterocyclic compounds are a diverse class of organic compounds and have been a cornerstone of medicinal chemistry. These compounds contain rings with at least two different elements and have emerged as a promising scaffold for the design of anticancer agents. The key heterocyclic compounds like Quinolones, Pyrazoles, and Triazoles exert different mechanisms of action to inhibit cancer cell growth. They can interact with biological macromolecules such as proteins and nucleic acids to modulate cellular signaling pathways. Cancer-specific pathways targeted by heterocycles can act by inhibiting cell cycle progression through modulating key regulators like Cyclin Dependent Kinases and Checkpoint Kinases. They potentially act by inhibiting the Phosphatidylinositol--Kinase/ Protein Kinase B (P13K/AKT) signaling pathway. Heterocyclic compounds can also induce apoptosis in cancer cells by activating pro-apoptotic proteins and inhibiting angiogenesis by targeting vascular endothelial growth factor. The design and synthesis of heterocyclic anticancer agents involve a combination of computational modeling, medicinal chemistry, and biological screening. Their ability to interact with specific cancer-related pathways and targets makes them attractive candidates for the design of targeted anticancer agents. This chapter will discuss the role of heterocyclic compounds in targeting cancer-specific pathways, highlighting their potential as therapeutic agents for treating various types of cancer.

Keywords: Angiogenesis, Apoptosis, Cellular signaling pathways, Dysregulation, Genetic predisposition, Heterocyclic compounds, Kinases, Lymphatic, Molecular mechanisms, Molecular pathway, Mutations, Proliferation, Pyrazoles, Quinolones, Signaling, Targeted anticancer agents.

* Corresponding author Nimisha Jain: Institute of Pharmacy, Rabindranath Tagore University, Bhojpur, Madhya Pradesh, India; E-mail: nimishajain28@gmail.com

INTRODUCTION

Overview of Cancer and Its Molecular Pathways

Cancer is a complex group of disorders that is defined by dysregulated cell proliferation, invasion of surrounding tissues, and the possibility of metastasis. It is the process by which cancer cells break free from the primary tumor, embark on a journey through the bloodstream or lymphatic system, and then spread to other body parts. Genetic predispositions, environmental exposures, and lifestyle choices converge to influence its progression.

Molecular foundations of cancer include changes to the genes that control regular cell processes, which result in aberrant cell behavior. At the molecular level, cancer is frequently characterized as a cell cycle illness, in which the breakdown of regulatory mechanisms causes cells to proliferate and divide uncontrollably. A detailed explanation of a cancer molecular pathway is given below in Fig. (1) [1].




Fig. (1). Cancer development pathway. (RAS: Rat Sarcoma virus; MYC: Myelocytomatosis oncogene; HER2: Human Epidermal Growth Factor Receptor 2. p53: tumor protein 53; BRCA1/2: Breast Cancer gene 1/2; RB1: Retinoblastoma1. Cyclin D/CDK4/6: Cyclin D, Cyclin-Dependent Kinase 4, and Cyclin-Dependent Kinase 6. BCL-2: B-Cell Lymphoma 2; BCL-XL: Member of the BCL-2 family; MCL-1: Myeloid Cell Leukemia. PI3K: Phosphatidylinositol-3-Kinase; AKT: Protein Kinase B; mTOR: Mammalian Target of Rapamycin; MAPK: Microtubule-Associated Protein Kinase; ERK: Extracellular Signal-Regulated Kinase; Wnt: Wnt Pathway; β-Catenin: β-Catenin Signaling Pathway. BRCA1/2: Breast Cancer Gene 1 and Breast Cancer Gene 2 [1].

Role of Small Molecules in Cancer Therapy

Small molecules are essential for cancer treatment because they target particular molecules that are part of the chemical processes that cause cancer to spread. These chemicals, which are usually either natural or synthetic, can interfere with cellular functions like metabolism, signaling, and DNA repair to stop tumor growth, encourage apoptosis, and even get past resistance mechanisms. Since they frequently have fewer adverse effects than conventional chemotherapy, they play a critical role in cancer therapy for the designed treatment.

Oncogene and tumor suppressor mutations cause cancer cells to become abnormal and begin to multiply at an uncontrollable rate. Some small molecules like Imatinib can inhibit oncogenes like RAS, MYC, and HER2 and Kinases (*e.g.*, Tyrosine Kinases). Uncontrolled cell division can be stopped by blocking the cell cycle with small molecules that inhibit Cyclin-Dependent Kinases (CDKs), *e.g.*, Palbociclib. Venetoclax is an example of inducing apoptosis, which focuses on apoptosis-related proteins (such as B-cell Lymphoma-2, also known as BCL-2, encouraging the cancer cells' death. Small molecules like Olaparib also take advantage of defective DNA repair in cancer cells; they inhibit DNA or genome repair enzymes such as Poly (ADP-ribose) Polymerase (PARP). Apart from these, there are so many examples of small molecules involved in cancer therapy, like Bevacizumab (Modulating Tumor Microenvironment {TME}), Everolimus (Inhibiting Key Signaling Pathways). For increasing the effectiveness of treatment, small molecules can be used in conjunction with radiation, immunotherapy, or chemotherapy.

Importance of Heterocyclic Compounds in Drug Discovery

Drug discovery has relied extensively on heterocyclic molecules for several decades. Their distinct chemical characteristics and structural diversity make them crucial for creating medications with great specificity and efficacy. Heterocyclic compounds will continue to be at the forefront of pharmaceutical innovation with more research and development, providing new avenues for treating a range of ailments, from cancer to infectious disorders and beyond. An outline of their significance is provided below in Fig. (2) [2].

INHIBITION OF ONCOGENIC SIGNALING PATHWAYS

Dysregulated signaling cascades governing cell growth, survival, and death often spark cancer's onset. Blocking oncogenic signals is a cornerstone of modern cancer treatment [3]. Faulty signal pathways that foster cell proliferation, survival, and metastasis, underlying numerous cancers. It may be possible to stop or reverse the progression of cancer by using therapeutic drugs that target these

CHAPTER 4

Design and Development of Novel Heterocycle Anticancer Agents

Lokkanya Dewangan¹, Anju Daharia² and Alok Singh Thakur^{1,*}

¹ Department of Chemistry, Shri Shankaracharya Institute of Pharmaceutical Sciences and Research, Shri Shankaracharya Professional University, Bhilai, Chhattisgarh, India

² Department of Chemistry, Kamla Institute of Pharmaceutical Sciences, Shri Shankaracharya Professional University, Bhilai, Chhattisgarh, India

Abstract: This chapter covers the strategies of design and development of heterocycles for cancer treatment, with a focus on the structural diversities and biological significances. It explores a variety of synthetic methods together with traditional and modern methods that include green chemistry strategies such as click chemistry and microwave-assisted synthesis; this improves the sustainability and efficiency of synthesis. This chapter also examines how these substances impact cancer, focusing on essential cellular pathways, hindering angiogenesis, and causing apoptosis. In addition, it highlights the way to use computational modeling, structure-activity relationship research, and rational drug design strategies to optimize these medications. The heterocyclic compound's potential for targeted, effective, and less noxious cancer treatments is highlighted, as is integration with sophisticated drug delivery systems and nanotechnology to boost effectiveness and lower toxicity.

Keywords: Anticancer agent, Computational modeling, Green chemistry, Heterocyclic compounds, Nanotechnology, Rational drug design.

INTRODUCTION

Millions of people are affected by Cancer, with an alarming number of new cases and fatalities reported each year, which continues to be the most extensive and scary disease. Even though there have been huge improvements in treatment options, traditional therapies like chemotherapy and radiation often have big troubles, such as drug resistance, unbearable side effects, and an inability to target cancerous cells [1, 2]. This imperative dispute has sparked an urgent search for novel curative molecules, especially those with improved efficiency and reduced

* **Corresponding author Alok Singh Thakur:** Department of Chemistry, Shri Shankaracharya Institute of Pharmaceutical Sciences and Research, Shri Shankaracharya Professional University, Bhilai, Chhattisgarh, India; E-mail: aloksinghthakur19852@gmail.com

toxicity. In this perspective, heterocyclic compounds have become a flicker of hope, with the potential to revolutionize cancer treatment and enhance patient outcomes globally.

A variety of chemical entities that can be engineered to show evidence of potent pharmacological activity are accessible through heterocyclic compounds. The fact that their ring structure contains one or more atoms of an element except carbon sets them apart. Amongst the heterocyclic compounds, benzothiazoles, pyrazoles, pyridines, and indoles have been verified to have noteworthy anticancer effects. Due to their distinctive arrangement of electron, steric, and chemical properties, these compounds are considered ideal scaffolds for drug design, which leads to specific binding with active sites of cancer targets such as DNA, enzymes, and cell surface receptors [3, 4].

Heterocycle compounds are immense for building chemotherapeutic agents since they can interact with a lot of different cancer targets, and they can be synthetically and structurally flexible. These ring structures, which have heteroatoms like nitrogen and sulfur in them, are great for targeting biomolecules like enzymes, receptors, and nucleic acids that play a crucial role in cancer, because they can form hydrogen bonds, harmonize with metal ions, and impersonate natural substrates [5]. Moreover, heterocyclic compounds also improve the pharmacokinetic features of therapeutic candidates by increasing their solubility, metabolic stability, and membrane permeability. As they are present in many FDA-approved anticancer drugs, which underscores their crucial role in attaining high binding affinity, potency, and reduced off-target toxicity, they are considered key lead molecules in the generation of novel anticancer agents [6, 7]. Furthermore, heterocycles have several advantages because of their ability to interact with various biological processes, such as hindering angiogenesis, promoting apoptosis, inducing cell cycle arrest, and disrupting DNA replication and repair processes. These properties make them attractive as impartial treatments or in combination with other therapies [8, 9].

A deep consideration of medicinal chemistry, cancer pathophysiology, and biological targets is necessary to develop novel heterocyclic anticancer agents. The process of discovering and enhancing lead compounds is being enhanced by high-throughput screening, computational modeling, and Structure-Activity Relationship (SAR) studies [10]. Researchers are now able to develop new lead molecules with high affinity for cancerous cells and limited adverse effects on normal cells. This level of accuracy is necessary for boosting patients' quality of life, with fewer side effects, and raises the overall therapeutic value of chemotherapeutic medications. By combining innovative methods of synthesis with principles of green chemistry, the requirement for methods of efficient,

economical, and environmentally sustainable synthesis to be translated from laboratory to clinical setting has become ever more crucial in the advancement of cancer treatment in recent years [11]. The full scope of heterocycles in cancer treatments involves multidisciplinary approaches comprising pharmacology, molecular biology, and synthetic chemistry.

This chapter addresses the development, synthesis, and biological assessment of heterocycles for cancer treatments and highlights the methods by which they work, the most recent advances in synthesis, and numerous heterocycles that demonstrate significant anticancer activity. To further develop cancer medication, the chapter covers a detailed review of the potential application of heterocycles in cancer drug discovery.

CHEMISTRY OF HETEROCYCLIC SCAFFOLDS IN ANTICANCER DRUG DESIGN

Heterocyclic compounds are a class of organic molecules that contain a ring structure composed of carbon atoms and at least one heteroatom, such as sulfur (S), nitrogen (N), or oxygen (O), within the ring. The heteroatom(s) within the ring system significantly influence the compound's electronic configuration, reactivity, and ability to interact with biological targets, making them valuable scaffolds for the design of drugs [12].

Classification of Heterocyclic Compounds

Alicyclic heterocyclic compounds: Alicyclic heterocyclic compounds (Fig. 1) are a subclass of aliphatic cyclic compounds that incorporate one or more heteroatoms (N, O, or S) within their non-aromatic ring structures. These systems retain aliphatic rings' conformational flexibility and saturated character while exhibiting unique chemical reactivity imparted by heteroatoms [13].




Fig. (1). Structure of alicyclic heterocyclic moieties.

Aromatic heterocyclic compounds: Aromatic heterocyclic compounds (Fig. 2) are cyclic organic structures in which one or more heteroatoms typically N, O, or S) are incorporated into an aromatic ring. These compounds exhibit delocalized π -electron conjugation, satisfying the criteria for aromaticity, and are widely

Clinical Applications and Case Studies

Venu Anand Das Vaishnav¹, Nishant Sudhir Jain^{1,*}, Vaibhav Maturkar¹ and Chhatrapal Patel¹

¹ Department of Pharmacy, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh, India

Abstract: This chapter provides a comprehensive exploration of heterocyclic chemistry, with a pivotal role in oncology. It begins with an overview of heterocyclic compounds, emphasizing their significance in drug discovery for cancer treatment. The fundamentals of these compounds are discussed in common scaffolds in anticancer agents. The chapter delves into the mechanisms of action, focusing on DNA interaction, damage, and enzyme inhibition by heterocyclic drugs. It highlights the clinical applications, showcasing heterocyclic drugs in chemotherapy protocols and emerging therapies. The following clinical trials have been explored for the clinical application of anticancer treatment. Case studies illustrate the efficacy of specific heterocyclic compounds, such as aspyridine derivatives in breast cancer, purine analogues in leukemia treatment, and indole-based compounds in prostate cancer. The chapter also addresses challenges and limitations, including drug resistance mechanisms and toxicity. It concludes with insights into future perspectives, including advances in computational drug design and trends in personalized medicine with heterocyclic compounds, underscoring their potential to revolutionize cancer therapy.

Keywords: Anticancer, Apoptosis, Biological, Carcinoma, Case studies, Clinical trials, Cynopyridine, DNA, Doxorubicin, Enzyme.

INTRODUCTION

Overview of Clinical Trials

Heterocyclic compounds have emerged as a promising class of molecules in oncology due to their diverse chemical structures and ability to target specific biological pathways involved in cancer progression. Clinical trials involving heterocyclic compounds focus on their potential as anticancer agents, exploring various mechanisms of action and therapeutic applications [1].

* Corresponding author Nishant Sudhir Jain: Department of Pharmacy, Guru Ghasidas Vishwavidyalaya, Bilaspur, Chhattisgarh, India; E-mail: nishant.s.jain@hotmail.com

Heterocyclic chemistry is regarded as a major subject in organic chemistry, and many of the existing publications in organic chemistry today are published in this area. Most of the natural products, such as carbohydrates, alkaloids (viz. reserpine, atropine, morphine), amino acids, proteins, nucleic acids, hemoglobin, hormones, enzyme cofactors, and vitamins, consist of heterocycles. Biologically important polymeric molecules are RNA (Ribonucleic Acid) and DNA (Deoxyribonucleic Acid), which periodically have heterocyclic structures made of nitrogenous bases such as adenine, guanine, cytosine, uracil, and thymine [2].

Role of Clinical Trials

The essential functions of such heterocycles almost on all fronts of the biochemical processes, including the conduction of nerve signals through the body, different chemical reactions to provide energy, the process of transferring genetic information, and vision, and the metabolism of each one of the living things, which are vital to support lives, render the evolution of the biochemistry often to be based on emulating such structural features [3]. The heterocyclic structure has frequently been found in multiple drug molecules due to the involvement of a variety of intermolecular interactions, including hydrogen bond donor/acceptor, metal coordination bond, van der Waals, pi-stacking, and hydrophobic bond, and such interactions assist the drug molecules in efficiently binding target enzymes and receptors in numerous different ways [4]. Cancers are of many types depending on the location of the cancer cells, including lung cancer, GIST (Gastrointestinal Stromal Tumors), lymphoma, myeloma, ovarian cancer, prostate cancer, breast cancer, bladder cancer, renal cell carcinoma, epithelioid sarcoma, *etc.* Of the top 10 diseases, cancers occupy eight places among the top 10 diseases, and even the first 2 out of the three most prevalent diseases are cancers: breast cancer (888 medications) and non-small cell lung cancer (832 medications), respectively. Table 1 displays some of the FDA-approved important drugs.

Table 1. Completed clinical trials and FDA-approved heterocyclic molecules for cancer treatment.

S. No.	Drug Name	Active Ingredient	Company Name	Molecular Target	FDA Approval Date	Clinical Use	References
1	Pemazyre	Pemigatinib	Incyte Corporation	FGFR1, FGFR2, FGFR3 and FGFR4	17/04/2020	Cholangiocarcinoma	[5] [6]
2	Tazverik	Tazemetostat	Epizyme, in collaboration with Eisai	EZH2	23/01/2020	Epithelioid sarcoma	[7] [8]

(Table 1) cont....

S. No.	Drug Name	Active Ingredient	Company Name	Molecular Target	FDA Approval Date	Clinical Use	References
3	Inrebic	Fedratinib	Celgene Corporation	JAK2	16/08/2019	Myelofibrosis	[9] [10]
4	Inqovi	Decitabine	Astex Pharmaceuticals	Nucleoside metabolic inhibitor	07/07/2020	MDS	[11] [12]
5	Koselugo	Selumetinib	AstraZeneca	MEK1/2	10/04/2020	NF1	[13] [14]
6	Pylarify	Piflufolastat	Progenics Pharmaceuticals Inc.	PSMA	27/05/2021	Prostate cancer	[15] [16]
7	Detectnet	Copper Cu-64 Dotatate Injection	RadioMedix, and Curium	somatostatin receptors	03/07/2020	Diagnosis of NETs	[17]
8	Piqray	Alpelisib	Novartis	PI3K	24/05/2019	Breast cancer	[18] [19]
9	Enhertu	Fam-trastuzumab	Daiichi Sankyo Company	HER2	20/12/2019	Breast cancer	[20] [21]
10	Tukysa	Tucatinib	Array Biopharma	HER2 and HER3	17/04/2020	Breast cancer	[22] [23]
11	Trodelvy	Sacituzumab	Immunomedics	Topoisomerase I inhibitor	22/04/2020	Breast cancer	[24] [25]
12	Rozlytrek	Entrectinib	Genentech, Inc.	NTRK	15/08/2019	NSCLC	[26] [27]
13	Tabrecta	Capmatinib	Novartis Oncology	c-Met/HGFR	06/05/2020	NSCLC	[28] [29]
14	Gavreto	Pralsetinib	Blueprint Medicines Corporation	RET	04/07/2020	NSCLC	[30] [31]
15	Tepmetko	Tepotinib	Merck	MET exon 14 skipping mutations	25/03/2020	NSCLC	[32]

CASE STUDIES OF HETEROCYCLIC COMPOUNDS IN CLINICAL PRACTICE

Case Study-1: Pyridine Derivative in Breast Cancer

Anti-Breast Cancer Activity Evaluation of Novel 3-Cyanopyridine Derivatives as PIM-1 Inhibitors

Several new cyanopyridine derivatives were synthesized for this study, and their anticancer potential against the MCF-7 breast cancer cell line was subsequently

Natural Products and Heterocycles in Cancer Therapy

Vidya Kakad¹ and Tripti Sharma^{2,*}

¹ Faculty of Pharmacy, Chhatrapati Shivaji Maharaj University, Navi Mumbai, Maharashtra, India

² Department of Pharmaceutical Chemistry, Bomaby College of Pharmacy, University of Mumbai, Mumbai, Maharashtra, India

Abstract: Cancer remains one of the most challenging diseases in modern medicine, with an urgent need for novel, effective therapeutic strategies. Natural products, particularly bearing a heterocyclic moiety, have long been a rich source of anticancer agents. This chapter explores the diverse roles of these heterocyclic bioactive molecules in cancer therapy, highlighting their mechanism of action and the potential of novel drug development. Heterocyclic compounds, in particular, have emerged as key scaffolds in anticancer drug design due to their ability to interact with biomolecular targets, including DNA, enzymes, and cell surface receptors. The chapter delves into the molecular mechanisms by which natural products with heterocyclic rings in their structure exert antitumor effects, such as inducing apoptosis, inhibiting angiogenesis, modulating the immune response, and interfering with cancer cell signaling pathways. It focuses on the role of natural heterocyclic compounds, particularly oxygen, nitrogen, and sulphur-containing scaffolds, which are utilized in the development of anti-cancer drugs. In addition, FDA-approved natural heterocyclic compounds are reviewed, showcasing their clinical relevance and therapeutic success. The chapter also discusses the challenges faced in the development and commercialization of natural heterocyclic agents, such as issues related to drug resistance, bioavailability, and toxicity. This chapter offers a thorough examination of the increasing importance of natural heterocyclic compounds in the field of cancer therapy, offering insights into both their current applications and their future potential in oncology drug development.

Keywords: Anti-cancer, Drug development, Heterocyclic, Natural product, Scaffold.

INTRODUCTION

Cancer incidence is increasing globally. While cancer is not the leading cause of death in the world, it is the second most common (and rising) with an estimated

* Corresponding author Tripti Sharma: Department of Pharmaceutical Chemistry, Bomaby College of Pharmacy, University of Mumbai, Mumbai, Maharashtra, India; E-mail: drtriptisharma22@gmail.com

19.3 million new cancer cases and 10 million deaths worldwide in 2020 [1]. Many heterocyclic anticancer drugs are now in use, many of them naturally occurring and others synthesized, and yet more are being sought. Heterocyclic compounds (ring compounds with a C atom and any of the atoms N, O, or S) have been investigated for the therapeutic potential in the treatment of many diseases, including cancer. Many active medications and natural substances are built from basic heterocyclic scaffolds. According to statistics, at least 85% of physiologically active compounds have either a heterocycle or have a single nitrogen atom in their structure [2]. The heteroatoms added improve solubility. By adding these heteroatoms, the druggable candidates' solubility and polarity and hydrogen bonding capability are enhanced, and ADMET (Adsorption, Distribution, Metabolism, Excretion, and Toxicity) optimization is achieved [3]. Therapeutic heterocyclic compounds such as 5-fluorouracil, orlistat, vandetanib, rapamycin, axitinib, sorafenib, epigallocatechin, doxorubicin, daunorubicin, and Taxol (Fig. 1) were shown to exhibit high inhibition against several cancer cell types [4]. Fig. (1) shows a couple of examples.




Fig. (1). The chemical structures of a few heterocyclic compounds used to treat different kinds of cancer.

Despite their effectiveness, chemotherapeutic drugs can also have an adverse reaction on normal cells, such as nausea, vomiting, mucositis, alopecia, neuropathy, and myelosuppression, among others. Also, they have been proven to be related to the undesirable characteristic of Multidrug Resistance (MDR), accounting for more than 90% of deaths to cancer patients caused by chemotherapy [5]. Molecular targets of natural products appear to affect several oncogenic signaling pathways simultaneously by changing their expression or activity. Different natural chemicals impact many processes, including apoptotic cell death, cell proliferation, migration/invasion, angiogenesis, and metastasis. Natural products can induce intracellular signalling pathways that activate processes leading to cancer cell death. Over 60% of the cancer chemotherapy and chemopreventive medications on the market today are either synthetic compounds made from natural prototype structures or natural compounds taken from plants or animals [6].

Natural items can be used to improve chemotherapy when cancer is not responding to conventional treatments. Finding more affordable and environmentally friendly alternatives has become more difficult for researchers due to the high cost of traditional medications and the growing prevalence of cancer [7]. Natural products are very beneficial in this situation because of their availability, low toxicity, chemical diversity, and safety, which make them a desirable and reasonably priced substitute for synthetic products.

Common problems related to cancer therapy are pharmacological resistance, systemic toxicity of the given medications, and pharmacological ineffectiveness. Finding an effective therapeutic agent to fight tumors has also been stumped by not only the confusing characteristics of the pathways (multiple signaling nature) but also the tendency of most cancer cells to change [8]. Therefore, there exists an urgent call for the discovery of new anticancer agents as the pharmacological lead [9]. Some problems with the effectiveness of chemotherapeutics are these: the syndrome of resistance and the complexity of the cancer problem necessitating a multidrug regimen for their successful handling of different types of cancer. With a focus on their mode of action, this chapter describes the many kinds of heterocyclic multimodal natural products as anticancer agents and their biological targets.

Heterocyclic Compounds as Anticancer Agents

Heterocyclic organic compounds are very important constituents of several architectures that have considerable pharmacological and biological significance. They form a convolutedly important group of compounds. They exhibit their own unique features, being favorable for a broad range of intermolecular interactions,

Heterocycles and Cancer Biomarkers

Ashish Majumdar^{1,*}, S Prakash Rao², Surendra Kumar Saraf¹ and Jitendra Patel³

¹ Department of Pharmaceutical Sciences, Columbia Institute of Pharmacy, Chhattisgarh Swami Vivekanand Technical University, Raipur, Chhattisgarh, India

² Department of Pharmacognosy, Shri Rawatpura Sarkar Institute of Pharmacy, Chhattisgarh Swami Vivekanand Technical University, Kumhari, Chhattisgarh, India

³ Department of Pharmacognosy, Datta Meghe College of Pharmacy, Datta Meghe Institute of Higher Education (Deemed to be University), Wardha, Maharashtra, India

Abstract: Heterocyclic compounds maintain essential importance within cancer research because they advance both diagnostic instrument development and personalized treatment systems. This chapter explains the essential role of heterocycles regarding cancer biomarkers for tumor discovery alongside diagnosis and therapy applications. Many medical indications link through cancer biomarkers to demonstrate disease progress and treatment effectiveness. Genetic markers are one type of function that modern biomarkers perform alongside their protein and epigenetic functions. The adaptable nature of heterocycles makes them suitable for biomarker modifications, thus becoming a crucial development for medical applications in precision oncology. A review of cancer biomarkers based on circulating tumor DNA, exosomes, and enzyme-linked indicators begins the chapter with related importance for disease detection. The following part examines how heterocyclic compounds present unique features while illustrating their core role in diagnostic probes and blood biopsy solutions, and targeted therapeutic developments. The efficacy of heterocyclic medicines for cancer treatment becomes clear through study examples, which show how these medications exploit particular biomarkers inside medical facilities. The chapter addresses essential matters, including stability, bioavailability, and drug resistance, while presenting useful solutions to overcome these obstacles. The article investigates artificial intelligence's ability to enhance biomarker-based cancer treatment through heterocyclic drug design. This section provides both present information combined with future perspectives about heterocyclic science advancements through biomarker research input. These compounds strengthen cancer treatment outcomes and create individualized therapy strategies for medical patients, according to the study findings.

* **Corresponding author Ashish Majumdar:** Department of Pharmaceutical Sciences, Columbia Institute of Pharmacy, Chhattisgarh Swami Vivekanand Technical University, Raipur, Chhattisgarh, India; E-mail: ashishmajumdar27@gmail.com

Keywords: Accessibility, Biomarkers, BRCA1/2, Cancer, Circulating tumor DNA (ctDNA), Clinical practice, Clinical treatment planning, DNA methylation, DNA sequencing, Disease progression.

INTRODUCTION

Medical science identifies cancer as a complex disease that remains the primary reason for mortality across the world. The recent developments in oncology and molecular biology enable a better understanding of cancer origins, which streamlines biomarker detection for the disease. Cancer biomarkers function as quantifiable indicators of biological conditions, so they have revolutionized oncological diagnosis, together with treatment prognosis monitoring and patient management. The study analyzes the fundamental bond between heterocyclic chemicals and cancer biomarkers for their potential use in enhancing precision medical approaches [1 - 3].

Overview of Cancer Biomarkers

Medical professionals depend heavily on cancer biomarkers shown in Fig. (1) because they provide a method to study tumor biological activity, together with treatment response and disease progression. The four groups of biomarkers we classify include genetic and epigenetic, as well as protein-based and innovative [4]. Successful cancer management requires genetic biomarkers KRAS, EGFR, and BRCA1/2 to operate properly [5]. The process of DNA sequencing remains unchanged since epigenetic markers rely on both DNA methylation methods and histone modification systems to manage genetic expression. The assessment and monitoring of cancer disease progression, together with clinical treatment planning, heavily rely on the employment of protein markers, including HER2 and PSA. Medical experts predict diagnostic tests will be transformed by circulating tumor DNA (ctDNA) and exosomes because they demonstrate significant advancements. Science has advanced to the point where these biomarkers become more suitable for research because scientists can detect and measure them with high accuracy using innovative methods. There is a need for innovative approaches to optimize biomarker use in clinical practice due to existing differences in biomarkers and their stability and accessibility [6].

Role of Heterocyclic Compounds in Modern Oncology

The field of oncology depends extensively on heterocyclic compounds in contemporary medicine. The ring-like structures in these chemical compounds contain nitrogen elements as well as oxygen, and sulfur. The diagnostic and therapeutic approaches for cancer depend on heterocyclic compounds due to their

unique structural design features and their ability to modify their functional attributes.




Fig. (1). Heterocyclic structures and their impact on cancer biomarkers.

Heterocycles enable scientists to develop fluorescent probes and imaging agents, and biosensors that enhance detection accuracy for cancer biomarkers [7]. Medical imaging works through quinoline-derived compounds that make biomarker observation possible during real-time procedures, so detection happens earlier. The examination of cancer through liquid biopsy relies on pyrimidine derivatives, which bind to ctDNA or exosomal proteins for non-invasive medical diagnosis [8].

Heterocyclic compounds function successfully to treat pathways that biomarkers influence during clinical therapy. Imatinib represents an exceptional molecular compound used for inhibiting BCR-ABL kinase activity to treat chronic myeloid leukemia effectively. Gefitinib attacks particular EGFR mutations that exist within non-small cell lung cancer cells. Heterocyclic molecules possess unique pharmacokinetic properties along with pharmacological characteristics that represent an emerging therapy approach against cancer better than traditional methods. These properties enhance drug dissolution and improve chemical stability at the same time as enabling more specific targeting of therapeutic targets.

CHAPTER 8

Drug Resistance and Heterocyclic Compounds

Rohini Armo¹, Deepika Singh¹, Rishi Paliwal^{2,*} and Anand Kumar³

¹ Department of Pharmachemistry, Shri Rawatpura Sarkar Institute of Pharmacy, Chhattisgarh Swami Vivekanand Technical University, Kumhari, Chhattisgarh, India

² Nanomedicine and Bioengineering Research Laboratory, Department of Pharmacy, Indira Gandhi National tribal University, Amarkantak, Madhya Pradesh, India

³ University Department of Pharmacy, Santgahira Guru University, Ambikapur, Chhattisgarh, India

Abstract: Heterocyclic compounds, which are ring structures containing at least two different elements—typically nitrogen, oxygen, or sulfur—are foundational in drug development due to their broad spectrum of biological activities. Cancer, a disease caused by genetic mutations leading to uncontrolled cellular proliferation, often develops resistance to therapeutic interventions. This chapter examines how heterocyclic compounds both contribute to and help overcome drug resistance, particularly in cancer therapies. Structural modifications in these compounds have shown promise in enhancing anticancer efficacy and reducing toxicity. Moreover, the chapter highlights recent research on heterocycles that counteract resistance mechanisms through multi-target approaches, efflux pump inhibition, and biofilm disruption. Future directions involve discovering novel molecular targets and designing next-generation heterocyclic agents for resistant cancer types. Strategies such as combination therapies and molecular inhibitors are also evaluated, aiming to provide a comprehensive insight into combating drug resistance through heterocyclic chemistry.

Keywords: Antibacterial, Anticancer, Antibiotics, Antifungal, Antiviral, Biofilm, Chemotherapy, Drug resistance, Efflux pumps, Enzymatic degradation.

INTRODUCTION

The effectiveness of medications, including antibiotics, remains reduced against their target disease according to the definition of drug resistance. Multiple genetic factors combined with targeting drug elimination pumps and enzymatic transformations, along with target receptor and biofilm formation mechanisms, drive this worldwide resistance problem [1]. An increasing number of infectious

* Corresponding author Rishi Paliwal: Nanomedicine and Bioengineering Research Laboratory, Department of Pharmacy, Indira Gandhi National tribal University, Amarkantak, Madhya Pradesh, India; E-mail: rishipaliwal@gmail.com

diseases show drug resistance, including both multidrug-resistant *Mycobacterium tuberculosis* and MRSA, and cancers develop drug-resistant tumor cells, which result in treatment failure [2]. The organic heterocyclic ring compounds contain other atoms beyond carbon and hydrogen through their structural framework with oxygen (oxa), nitrogen (aza), and sulfur (thio). The pharmacological effects of these compounds arise from their diverse ring structures and heteroatom combinations and saturation states, and ring sizes across 3 to 7 members. The skeletal structure of antibacterial drugs includes pyridine, which occurs naturally in niacin, along with imidazole and triazole that form fungal drug ketoconazole, while antimalarial chloroquine and anticancer and neurologic medications utilize the indole ring structure [3]. Heterocyclic chemistry proves effective for therapeutic drug development because it provides a robust method to fight drug resistance. Medical scientists develop pharmaceutical compounds that utilize multiple targets (multi-target inhibitors) or operate against efflux pumps and alternative drug targets while also affecting biofilms. These compounds play a crucial role in developing new pharmaceutical agents against strains of resistant bacteria, viruses, and cancer microorganisms [4, 5]. Oncology drug resistance behaves as an essential obstacle that blocks appropriate treatment results. The two categories of resistance consist of intrinsic resistance together with extrinsic resistance, which develops over time [6, 7]. Tumor cells naturally display resistance to medication treatment before experiencing any contact with therapeutic agents. Tumor heterogeneity combined with pre-existing mutations, along with drug efflux mechanism activation, make up the main reasons behind this form of resistance. Oncogenic signaling occurs together with enhanced DNA repair capacity (Fig. 1) and changed drug targets that activate compensatory pathways as intrinsic factors. TNBC (Triple-negative Breast Cancer) specifically becomes resistant to hormonal therapy as a result of its built-in resistance mechanisms, and BRAF (V- Raf Murine sarcoma viral oncogene homolog B1) inhibitors face failure against melanomas due to new signaling pathways becoming activated [8 - 13]. The process of treatment leads to extrinsic resistance development in tumors through adaptive modifications of previously treatment-responsive cells. Drug resistance mechanisms include elevated drug target expression together with alternative pathway initiation and increased DNA maintenance and TME (Total Mesorectal Excision) structural changes. The development of resistance in ovarian cancer cells is associated with DNA repair pathway modifications, whereas drug resistance to immune checkpoint inhibitors, e.g.; PD-1/PD-L1 stems from diminished antigen-presenting potential [12 - 15]. Cancer develops resistance mechanisms through both inherited factors and acquired elements, which affect multiple cancer types and treatment substances. Some pathways that sustain resistance play a role in both intrinsic and acquired forms of cancer treatment resistance, according to recent research [16, 17].




Fig. (1). Types of mechanisms of resistance to current targeted therapies.

Acquired resistance develops from cellular and molecular activities that include (a) genetic mutations or expression modifications enabling target drug resistance, (b) secondary proto-oncogene activation after treatment, (c) tumour drug metabolism changes, and (d) drug target changes, as shown in Fig. (2). These factors arise during cancer treatment. Resistant mechanisms in cancer occur for various reasons, including (f) the transmembrane transporter ABC efflux mechanism that results in drug removal, (g) epigenomic changes that modify receptors through acetylation and methylation, or microRNA changes, and (h) alterations in post-treatment TME. The mechanisms can act by themselves or together to produce multidrug resistance, which is recognized by both references [16 - 18]. Numerous anticancer medications require metabolic activation to demonstrate efficacy in practical usage. Drug resistance in cancer cells occurs when these cells lower the activation process of therapeutic agents [19]. Acute myelogenous leukemia receives treatment through the use of cytarabine (AraC) medications. AraC needs multiple phosphorylation steps to become the active drug metabolite AraC-triphosphate. When either mutations or downregulation occur within the activation pathway, it decreases AraC activation, which leads to drug resistance. Biological systems use three significant mechanisms to activate and inactivate drugs, which include the cytochrome P450 (CYP) system alongside the glutathione-S-transferase (GST) superfamily and the uridine diphosphoglucuronosyl transferase (UGT) superfamily [19 - 22]. The cancerous population demonstrates MDR ability, which allows them to fight off different types of drugs that belong to variable chemical groups and employ multiple action mechanisms [21]. The inability of chemotherapy to treat human cancers mainly arises from this factor. The scientific community demonstrates that diverse molecular mechanisms trigger the development of MDR. A drug's toxic effects undergo delays when cells

CHAPTER 9

Toxicity and Safety Assessment of Heterocyclic Anticancer Agents

Gaurav Kesharwani^{1,*}, Ankit Mishra¹, Pranali Mishra² and Smriti Dewangan³

¹ Faculty of Pharmacy, VNS Group of Institutions, Rajiv Gandhi Proudhyogiki Vishwavidyalaya, Bhopal, Madhya Pradesh, India

² Swami Vivekanand College of Pharmacy, Rajiv Gandhi Proudhyogiki Vishwavidyalaya, Bhopal, Madhya Pradesh, India

³ Amity Institute of Pharmacy, Amity University Chhattisgarh, Raipur, Chhattisgarh, India

Abstract: The development of active pharmaceutical ingredients, including anticancer agents, frequently involves the utilization of heterolytic compounds due to their ability to interact with biological targets and diverse physicochemical properties. Development of these anticancer agents containing heterocyclic structures requires a scientific stepwise approach. These Heterocyclic Anticancer Agents (HAA) are necessary not only to show significant therapeutic promises but also to be safe. The research on HAA toxicity and safety analysis covers recently published reports involving *in-silico*, *in-vitro*, preclinical, and clinical evaluations. The physicochemical and structural analysis of the compounds leads to toxicity manifestations, while various mechanisms contribute to these toxic effects. The research team examined new *in-silico* prediction methods that use artificial intelligence for their predictions. The study incorporates OECD standard guidelines to evaluate chemicals and anticancer agents. The toxicity and safety studies of HAA are presented through tables in recently published scientific works. The success rate of HAA and patient safety depends on integrating safety evaluation at the early stages of drug discovery.

Keywords: Anticancer drugs, Cancer pathways, Chemical reactivity, Clinical use, DNA, Drug resistance, Drug-target interactions, Enzyme-binding pockets, Epigenetic medications.

INTRODUCTION

The discovery of medications heavily relies on heterocyclic substances as essential chemical frameworks. Their capability to reproduce biological compounds such as amino acids and nucleotides, along with carbohydrates, makes them valuable [1]. Organic chemical compounds with atoms from multiple eleme-

* Corresponding author Gaurav Kesharwani: Faculty of Pharmacy, VNS Group of Institutions, Rajiv Gandhi Proudhyogiki Vishwavidyalaya, Bhopal, Madhya Pradesh, India; E-mail: drankitmishravns@gmail.com

nts in a single ring make up heterocyclic compounds. Most heterocyclic compounds contain carbon (C) and at least one heteroatom such as nitrogen (N), sulphur (S), or oxygen (O) [2]. The development of medical treatments requires heterocyclic molecules because almost all approved medications have at least one heterocyclic structural component. As a fundamental field of organic chemistry research, heterocycles continue to evolve into a critical area of scientific investigation because of their multiple medical applications, as well as antimicrobial functions and industrial uses. The synthesis of vitamins, DNA, RNA, haemoglobin, and chlorophyll requires heterocyclic rings [3].

The development of anticancer medications has relied heavily on heterocycles, which are prevalent. They are essential to the design of anticancer therapies, and anticancer medicinal compounds currently on the market are heavily featured [4]. They also make up over 80% of the medications accessible for clinical use due to their distinct chemical reactivity. They comprise a vast collection of compounds with remarkable heteroatom differences. Heterocycles have proven crucial for developing anticancer drugs precisely because of their similarities to the biological molecules. Unsurprisingly, heterocycle-based compounds have frequently served as the foundation for anticancer therapy since they represent an extensive cohort of molecules with high flexibility regarding the interactions they can engage [5]. Heterocycles are a good option when creating compounds that will interact with targets and interfere with the biological pathways linked to the advancement of cancer because many enzyme-binding pockets are inclined to engage with heterocyclic moieties. The development of anticancer drugs relies heavily on heterocyclic scaffolds because of their capacity to overcome drug resistance, generate meaningful drug-target interactions, and modify critical cancer pathways [6]. As pharmacophores, they are crucial in kinase inhibitors, redox modulators, DNA-interacting compounds, and epigenetic medications. Heterocycles' adaptability makes them essential to anticancer medicinal chemistry and guarantees their continuous importance in drug discovery in the future [7].

The goal of developing anticancer drugs is always to maximize therapeutic efficacy while reducing side effects [8]. Targeting cancer cells is challenging since they share many biological characteristics with healthy cells. Anticancer medication development is a complicated process that calls for a multifaceted approach to strike a balance between efficacy and safety [9]. Prodrug design, nanoparticle delivery, targeted therapy, and personalized medicine have significantly improved the safety profile of anticancer drugs. However, issues like TME complexity, off-target toxicity, and resistance still exist. Precision oncology, where medications are customized to the genetic and molecular characteristics of a patient's cancer, holds the key to the future of anticancer treatment by reducing toxicity and optimizing effectiveness [10].

TOXICITY MECHANISMS OF HETEROCYCLIC ANTICANCER AGENTS

The ability of heterocyclic anticancer drugs to target particular biochemical pathways involved in cancer cell growth, survival, and metastasis makes them widely used [11]. The specific heterocyclic molecule type may affect their mechanisms, but common ones include DNA interaction, enzyme inhibition, metabolic toxicity due to mitochondrial interaction, and cellular signalling pathway regulation [12]. Apoptotic and necrotic cell death are the two primary forms; necrotic cell death involves the death of a group of cells within tissue and is caused by severe cellular damage. Apoptosis is a controlled type of cell death that can be programmed into the cell or induced, such as during development [13]. Particular DNA alterations and the absence of an inflammatory response distinguish it. If errors in DNA replication are found, it may be set off. Mutations would be preserved in subsequent cell divisions if this protective mechanism were lost, allowing mutant cells to proliferate and divide [14].

Radiation therapy and numerous cytotoxic anticancer medications work by causing cancer cells to undergo mutations that are not enough to kill the cell, but that the cell can recognize and use to trigger apoptosis. Necrotic cell death occurs when groupings of cells within a tissue die due to severe cell damage [15]. It can be generated or pre-programmed into the cell (for example, during development). It may be set off if errors in DNA replication are found [16]. Some important USFDA-approved drugs containing heterocyclic rings are presented in Fig. (1).




Fig. (1). USFDA-approved anticancer agents containing heterocyclic rings.

CHAPTER 10

Heterocycle in Cancer Prevention and Chemoprevention

Anup Kumar Patra¹, Aruna Ghose², Jasaswi Ray¹, Rajashree Mohanty¹ and Shakti Ketan Prusty^{2,*}

¹ Department of Pharmaceutical Analysis, College of Pharmaceutical Sciences, Biju Patnaik University of Technology, Puri, Odisha, India

² Department of Pharmacology, School of Pharmaceutical Sciences, Siksha'o' Anushandhan Deemed to be University, Bhubaneswar, Odisha, India

Abstract: Cancer remains a major global health challenge, characterized by abnormal and uncontrolled cell growth, with late-stage cancers often proving incurable despite advances in treatment. The urgent need for novel, potent bioactive molecules has intensified research efforts toward the development of new lead compounds and biological targets. Among various strategies, heterocyclic compounds have gained prominence due to their remarkable pharmaceutical properties, including strong anticancer activities. Several clinically used drugs like methotrexate, vinblastine, vincristine, daunorubicin, 5-fluorouracil, and doxorubicin are known to have heterocyclic cores that improve their physical and biological attributes. More than 85% of FDA-approved drugs incorporate heterocyclic frameworks, highlighting the critical position of heterocycles in contemporary medicinal chemistry. Heterocycles are versatile and dynamic scaffolds that can engage with various biological targets like genes, enzymes, and receptors essential for the progression of cancer. This study centres on FDA-approved heterocyclic anticancer agents, discussing their biological targets, mechanisms of action, synthetic approaches, and limitations. A detailed analysis of natural and synthetic heterocyclic compounds reveals their effectiveness for cancer treatment. The current investigation of heterocyclic frameworks presents new possibilities for creating innovative anticancer medications that address the challenges of drug resistance along with cancer heterogeneity.

Keywords: Anticancer, Bioactive, Chemotherapy, Drug resistance, Enzymes, Fda-approved, Genes, Heterocycles, Heterogeneity, Lead compounds, Mechanism, Medicinal, Natural, Pharmaceutical, Receptors, Scaffolds, Synthesis, Targets, Therapeutic, Treatment.

* Corresponding author Shakti Ketan Prusty: Department of Pharmacology, School of Pharmaceutical Sciences, Siksha'o' Anushandhan Deemed to be University, Bhubaneswar, Odisha, India; E-mail: shaktiketanprusty@soa.ac.in

INTRODUCTION

Overview of Cancer and Chemoprevention

Cancer arises as a disease that shows uncontrolled and unregulated cell division, besides cellular migration. Without treatment, it might ultimately result in the patient's death. Cancer can strike any body organ because of various factors like genes, personal lifestyle, infections, radiation, *etc.* The biggest cause of cancer is tobacco, which accounts for most cases of lung cancer. Ultraviolet rays from sunshine and radiation you may encounter in hospitals or certain industries increase your chance of developing cancer. People can become exposed to carcinogens such as asbestos and industrial chemicals by working or living in hazardous situations. A bad diet, being overweight, and not exercising enough are important lifestyle-related reasons for cancer. Besides, when someone drinks too much alcohol and is also born with genetic mutations, for instance, BRCA1 and BRCA2, their chances of cancer increase [1, 2].

The illness appears in all body organs due to genetic factors combined with environmental conditions and individual habits. The most frequent causes of cancer include tobacco consumption, along with infections and radiation exposure, environmental contaminants, and dietary choices [3]. Doctors categorize cancer types by their origin tissue or organ, which includes carcinoma, sarcoma, leukemia, and lymphoma. The development of cancer typically occurs in stages, beginning with initiation (genetic mutations), followed by promotion (cell proliferation), and progression (invasion and metastasis) [4]. These steps can span many years, providing a window of opportunity for preventive strategies. One such preventive strategy is chemoprevention. Chemoprevention refers to the use of natural or synthetic substances to stop, delay, or reverse the development of cancer [5]. The goal is to reduce the risk of cancer by intervening before the disease becomes clinically evident. Chemopreventive agents can work through a variety of mechanisms [6]. They may block the initiation phase by neutralizing carcinogens, enhance the repair of damaged DNA, inhibit cell proliferation, induce apoptosis (programmed cell death), or suppress inflammation and oxidative stress. These agents are classified into three categories based on their action:

- **Primary Chemoprevention** – used in healthy individuals to prevent the first occurrence of cancer.
- **Secondary Chemoprevention** – used in individuals with precancerous lesions to prevent progression to malignancy.
- **Tertiary Chemoprevention** – used in cancer survivors to prevent recurrence or the development of new cancers.

Many dietary components have been studied for their chemopreventive properties [7]. These include antioxidants (like vitamins C and E), phytochemicals (like flavonoids, polyphenols, and carotenoids), and minerals (such as selenium and zinc). Some well-known chemopreventive agents include:

- **Aspirin and NSAIDs (nonsteroidal anti-inflammatory drugs):** These are known to reduce the risk of colorectal cancer by inhibiting Cyclooxygenase Enzymes (COX), which play a role in inflammation and tumor development.
- **Tamoxifen and raloxifene:** These Selective Estrogen Receptor Modulators (SERMs) are used to prevent breast cancer in high-risk women.
- **Finasteride:** This drug is used to lower the risk of prostate cancer by reducing levels of the hormone dihydrotestosterone (DHT) [8].

Despite promising results, chemoprevention faces several challenges. Not all agents are effective for everyone, and long-term use may carry risks or side effects. Additionally, identifying individuals who would benefit the most from chemopreventive strategies remains a complex task. Therefore, ongoing research is essential to develop safer and more effective agents [9].

Importance of Heterocycles in Medicinal Chemistry

Heterocycles are among the most important classes of organic compounds in medicinal chemistry. A heterocyclic compound that contains at least one atom other than carbon, commonly nitrogen, oxygen, or sulfur, as part of the ring. These atoms are known as heteroatoms, and their presence drastically changes the chemical and biological properties of the molecule [10]. Heterocycles are found in the largest number of natural products, drugs, and bioactive molecules, making them useful in drug discovery and development. By changing the type and position of the heteroatom(s), chemists can fine-tune the physical, chemical, and pharmacokinetic properties of a compound, such as solubility, stability, lipophilicity, and the ability to cross biological membranes [11]. Heterocycles often serve as key pharmacophores—the active components of a drug molecule that bind to biological targets like enzymes or receptors. For instance, nitrogen-containing heterocycles can form hydrogen bonds with amino acid residues in the active sites of enzymes, improving the binding affinity and specificity of the drug [12]. Many of the most widely used drugs contain heterocyclic structures. Some prominent examples include:

- **Penicillin:** Contains a β -lactam ring, a four-membered nitrogen-containing heterocycle essential for its antibacterial activity.
- **Ciprofloxacin:** It is a fluoroquinolone-class antibiotic used in the treatment of bacterial infections [13].

CHAPTER 11

Multidisciplinary Approaches to Heterocyclic Oncology Research

Vinita Goti¹, Anchal Verma^{1,*} and Rohini Armo²

¹ Department of Pharmacology, Shri Rawatpura Sarkar Institute of Pharmacy, Chhattisgarh Swami Vivekanand Technical University, Kumhari, Chhattisgarh, India

² Department of Pharmachemistry, Shri Rawatpura Sarkar Institute of Pharmacy, Chhattisgarh Swami Vivekanand Technical University, Kumhari, Chhattisgarh, India

Abstract: Their unique chemistry and wide range of properties, heterocyclic compounds are used as the basic structure in many anticancer drugs. Current oncology studies make better use of different disciplines when trying to uncover and use heterocyclic compounds. This book chapter underlines approaches that bring together synthetic, computer-assisted, molecular biology, and medical ideas to help apply heterocyclic-based drugs to cancer treatments. With new approaches in SAR analysis, high-throughput screening, and AI, experts are finding more heterocyclic scaffolds likely to work against cancer. In addition, studying tumors using systems biology and genomics shows which molecules to address and how resistance to drugs develops, which makes it simpler to design the right heterocyclic compounds. Working together in research, scientists are changing cancer medicine by focusing therapies precisely on each patient's condition.

Keywords: Bioinformatics, Cancer drug resistance, Cancer therapy, Chemotherapy, Clinical translation, Computational drug design, Drug discovery, Green chemistry, Heterocyclic compounds, Immunotherapy.

INTRODUCTION

Cancer treatment presents a number of challenges, from traditional methods like chemotherapy and radiation therapy to novel approaches like targeted therapy, immunotherapy, stem cell transplantation, and hormone therapy. Various treatments are used. Therefore, to improve the prognosis and quality of life for cancer patients, a multidisciplinary approach is required to identify new therapeutic procedures [1]. Uncontrolled cell proliferation and the capacity to invade or spread to other parts of the body are characteristics of cancer, a complex

* Corresponding author Anchal Verma: Department of Pharmacology, Shri Rawatpura Sarkar Institute of Pharmacy, Chhattisgarh Swami Vivekanand Technical University, Kumhari, Chhattisgarh, India; E-mail: anchalvrm9@gmail.com

and diverse group of ailments rather than a single illness. Understanding and treating cancer necessitates a multidisciplinary approach (Fig. 1) due to its complexity. Numerous fields are involved in cancer research, including genetics, molecular biology, epidemiology, bioinformatics, engineering, and behavioral sciences.




Fig. (1). Impact of multidisciplinary research.

Increasingly, research on drug discovery involves highly integrated interdisciplinary teams and the use of modern technology. Research on cancer is a prime example of the value and necessity of interdisciplinary cooperation. The collaborative efforts of scientists, doctors, engineers, data analysts, and public health specialists are essential for cancer advancement, from molecular discoveries to societal treatments. Future innovations will depend on promoting integrated research frameworks and cross-disciplinary communication.

Heterocyclic compounds are basic components of both living matter and the chemistry of other materials around us [2].

Since most medications on the market today contain heterocycle compounds and heterocycle fragments, as well as their inherent adaptability and distinctive physicochemical characteristics, they have established themselves as genuine pillars of medicinal chemistry.

Despite their enormous contribution to chemotherapeutics for the treatment of numerous diseases, little is known about heterocyclic compounds and their multimodal anticancer characteristics. This is true for both synthetic and natural products [3].

Multidisciplinary research has become a key factor in advancing technology and scientific understanding. This method encourages creative solutions to challenging issues that cannot be sufficiently addressed by single-discipline

research by combining many fields. The impact of multidisciplinary research on speeding up scientific and technological advancements improves [4].

- **Faster Discovery:** Combining efforts accelerates the identification of lead compounds.
- **Reduced Failure Rates:** Early identification of poor candidates saves resources.
- **Better Patient Outcomes:** More targeted and effective cancer therapies.
- **Innovation Synergy:** Different scientific perspectives create novel solutions.

Currently, several heterocyclic chemical substances are available commercially as anti-cancer drugs.

Integration of Chemistry, Biology, and Medicine in Heterocycle Research

Heterocycle research is an area where organic chemistry, biological function, and medical application converge. Both natural and artificial medications contain these cyclic molecules, which have atoms like nitrogen, oxygen, or sulfur in their rings. In more than 75% of FDA-approved medications, at least one heterocyclic moiety is present. This integration provides a strong foundation for creating more specialized and efficient therapies [5].

Chemistry of Heterocycle compounds for Oncology research

Heterocyclic compounds are made up of both carbon and non-carbon atoms and have molecules with rings containing atoms. They have a crucial structural foundation for numerous chemicals with pharmacological and biological value. The research on heterocyclic compounds is an important part of organic chemistry and is utilized extensively in many industries and Pharmaceutical medicine. In recent decades, many novel heterocyclic targeted drugs have emerged and played a special role in the treatment of cancer. Molecular targeted therapy is a key element of emerging treatment in comprehensive multidisciplinary cancer treatment [6].

The chemical foundation of many anticancer medications utilized in clinical settings is made up of heterocyclic molecules. As anticancer medicines, heterocyclic compounds have demonstrated a great deal of promise. These are organic compounds with a cyclic structure that includes at least one heteroatom, such as sulfur, oxygen, or nitrogen [7, 8]. The chemistry of monocyclic, polynuclear, and heterocyclic molecules containing nitrogen, oxygen, and sulfur is important for biological processes and has potential applications in medical chemistry. The anticancer activities of a number of heterocyclic chemical families have been thoroughly investigated [9, 10].

Emerging Trends and Novel Approaches

Gunjan Kalyani^{1,*}, Disha Kesharwani¹, Monika Bhairam¹ and Sandhya Mishra¹

¹ Columbia Institute of Pharmacy, Chhattisgarh Swami Vivekanand Technical University, Raipur, Chhattisgarh, India

Abstract: The majority of heterocycle compounds and generally frequent heterocycle fragments found in various medications currently on the market have established them as fundamental building blocks of medicinal chemistry due to their inherent adaptability and distinctive physicochemical characteristics. Furthermore, various medications are successfully marketed in the market; numerous other such medications are being researched for their potential as a first line therapeutic agent for various categories of cancers. Oncology research has particularly employed the intrinsic flexibility and versatile core structure of these heterocyclic molecules. However, heterocyclic compounds have drawbacks just like any other promising anticancer medication. A brief overview of various heterocyclic active chemicals and families along with their primary medical uses are thoroughly discussed. While concentrating on cancer treatment, the primary biochemical mechanisms of action, biological targets, structure-activity connections, and intrinsic constraints in the application of these substances are the major highlights. Finally, the basic characteristics and implications of nanovectorization of such compounds have been explored in light of the integration of nanotechnology for efficacious selective targeting of pharmaceuticals, which enhances the pharmacokinetic/pharmacodynamic properties of heterocyclic compounds. Along with providing a concise overview of the role of heterocyclic scaffolds in varying chemotherapy regimens, the assessment of ongoing pre-clinical and clinical research on heterocyclic compounds with potential therapeutic utility against a vast range of cancers has also been reviewed. The chapter's major goal is to draw attention to crucial heterocyclic scaffolds that have been utilized in recent antitumor drug design and that the drug development community should focus on further in order to produce safer and more effective targeted small-molecule anticancer medicines.

Keywords: Accelerated approval, Cancer recurrence, Cancer therapeutics, Drug delivery, Heterocyclic compounds, Immunotherapy, Immunosurveillance, Nanopharmaceuticals, Nitrogen and oxygen -based heterocycles, Oncology.

* Corresponding author Gunjan Kalyani: Columbia Institute of Pharmacy, Chhattisgarh Swami Vivekanand Technical University, Raipur, Chhattisgarh, India; E-mail: kalyani.gunjan@yahoo.in

INTRODUCTION

Cancer, characterized by unchecked cell growth and division, continues to be a major global health concern. In 2018, it was the second leading cause of death globally, accounting for over 9.6 million deaths, or around one in six mortality rate, according to the WHO. Around 1.39 million incident cases of a wide range of cancers were projected in India in the ICMR's National Cancer Registry Program Report 2020; estimates indicate that number could increase to 1.57 million by 2025. Even though treatment has evolved, full cures for advanced-stage cancer are still elusive, which emphasizes how urgently new, potent bioactive chemicals must be developed. To fight this debilitating illness, researchers worldwide are concentrating on finding new medicinal compounds [1].

One or more heteroatoms, *i.e.*, non-carbon atoms, such as nitrogen, oxygen, or sulfur, are included in cyclic structures that define heterocyclic compounds, a broad category of organic molecules. The word “hetero” is derived from the Greek word “heteros,” which means “other” and emphasizes the fact that these non-carbon atoms are part of the ring structure [2, 3]. These substances' biological action across a range of illnesses makes them essential in many biological applications. It is noteworthy that many anti-cancer drugs contain heterocyclic compounds. The FDA authorized nearly two-thirds of novel molecular anti-cancer medications between 2010 and 2015, demonstrating the significance of heterocyclic rings in contemporary drug development. The continuous development of therapeutic medicines for cancer and other disorders depends on heterocyclic compounds because of their adaptability and effectiveness [4 - 6]. Because of their heteroatoms, heterocyclic compounds have special physicochemical characteristics that enable them to act as bases or acids depending on the pH of the surrounding environment. They are common in biological systems because of their adaptability, which enables a variety of interactions. They can interact with enzymes efficiently because of their capacity to participate in a variety of intermolecular interactions, including metal coordination, π -stacking, hydrogen bonding (as donors and acceptors), van der Waals forces, and hydrophobic interactions [7, 8].

Since the various ring sizes and configurations of heterocycles can fit into the binding pockets of enzymes in a variety of ways, their structural diversity complements these pockets. This flexibility is especially useful for cancer treatments that target cellular pathways linked to growth and development. The chemical space of heterocyclic rings may also be easily expanded by adding different substituents, which makes them perfect for the development of anti-cancer drugs [8]. As a result, the development of anti-tumor drugs now heavily

relies on heterocyclic structures, which are seen in many of the current treatments. Adaptable structures and links with other structures allow them to be important in ongoing cancer research. We can classify effective anticancer heterocyclic compounds by considering which heteroatom forms part of their structure. Fig. (1) clarifies the types of heterocyclic compounds. There are three main categories that these substances fall into:




Fig. (1). Classification of heterocyclic compounds based on ring size and heteroatoms.

Nitrogen-based heterocyclic compounds: Many biologically active heterocyclic compounds with nitrogen include purines, pyrimidines, and indoles. They encourage cells to stop reproducing by interacting with DNA, enzymes, and receptors associated with survival and dysfunction.

Oxygen-based heterocyclic compounds: Three oxygen-containing heterocyclic compounds, purines, pyrimidines, and indoles, are the major oxygen-based heterocyclic compounds. Their ability to connect with different biological structures, amongst them forming hydrogen bonds, makes them very efficient.

Heterocyclic compounds based on sulfur: Heterocyclic compounds containing sulfur, such as benzothiophenes and thiophenes, are also known to have anticancer effects. An essential component of the molecular interactions that can stop the growth of cancer cells or cause apoptosis is the sulfur atom [9]. Important candidates for the creation of novel anticancer medications are the chemicals found in each of these

SUBJECT INDEX

A

Absorption 40, 84, 143, 198, 203, 234, 236
Acetylation 58, 171
Activating transcription factor 4 (ATF4) 124
Activation 36, 52, 57, 75, 106, 174, 181, 220, 222, 229, 236
Acute myeloid leukemia (AML) 30, 39, 271, 275
Adverse events (AEs) 199, 200, 205
Alkaloids 8, 99, 117, 120, 122, 125, 179, 224, 225, 226, 228
Alkylation 78, 80
Angiogenesis 22, 23, 54, 55, 80, 82, 150, 152, 223, 227, 230, 250, 253
Angiogenesis inhibitors 55, 223
Anthracyclines 12, 77
Antimetabolites 26, 74, 119, 130, 218
Antioxidants 25, 103, 196, 217, 219, 220, 221, 225, 239
Apoptosis 25, 48, 54, 70, 71, 77, 78, 81, 103, 120, 121, 123, 193, 194, 222
Aromatic heterocycles 6, 227
Aromatic rings 3, 197, 227
Aspartate aminotransferase (AST) 198, 199
Assays 88, 196, 203
Autophagy 120, 123, 174, 194, 231
Axitinib 34, 82, 115, 127, 178, 223, 283

B

Benzene 30, 34, 39, 52, 226, 227, 228
Benzimidazole derivatives 40, 83, 179, 253
Benzimidazoles 39, 40, 81, 83, 221, 227
Benzothiazoles 53, 54, 71, 77, 220
Bioavailability 5, 82, 90, 91, 153, 198, 202, 229, 238, 254, 255
Biomarkers 136, 137, 139, 140, 141, 142, 145, 146, 147, 149, 150, 156, 157, 198, 199
Blood urea nitrogen (BUN) 106, 199
Blood vessels 82, 150, 175, 224

B-cell lymphoma-2 (Bcl-2) 49, 50, 54, 79, 82, 121, 122, 124
Breast cancer gene (BRCA) 49, 56
Bruton's tyrosine kinase (BTK) 26, 119, 282

C

Camptothecin 12, 30, 75, 125, 218, 224, 225
Carcinogenesis 25, 52, 220, 225, 235
Carcinogenicity 198, 204, 235
Cardiotoxicity 196, 199, 200
Caspases 54, 121, 122, 222
Cell cycle 12, 28, 50, 52, 222, 223, 253
Cell lines 34, 88, 101
Cell membranes 40, 78, 206
Cellular macromolecules 194, 195
Chemopreventive agents 216, 217, 235, 236
Chemotherapeutics 116, 180, 247
Chemotherapy 55, 56, 57, 59, 107, 108, 116, 169, 171, 205, 206, 234, 236, 246, 281
Chromatin 59, 60, 140, 230
Chromatin remodeling 39, 58, 59
Chronic lymphocytic leukemia (CLL) 127, 275, 280
Chronic myeloid leukemia (CML) 11, 13, 89, 126, 129, 151, 175, 230, 234, 255
Circulating tumor DNA (ctDNA) 136, 137, 141, 142, 146, 158
Cisplatin 13, 14, 83, 105, 106, 173, 174
Clinical trials 87, 89, 98, 99, 197, 198, 200, 201, 203, 234, 235, 257, 258
Computer-aided drug design (CADD) 82
Coumarins 4, 117, 158, 180, 219, 221, 226, 273
Creatinine 198, 199
Cytokines 141, 142, 199, 221, 282, 283
Cytotoxicity 194, 196, 198, 207, 235, 258, 279, 281
Cytochrome P450 (CYP) 171, 173, 195, 220
Cyclin-dependent kinases (CDKs) 49, 50, 223

D

Dendrimers 90, 253, 279, 284
Dihydropyridines 6, 85
Dissemination 108, 223
Distribution 26, 40, 115, 143, 198, 206, 234, 236
DNA interaction 12, 25, 78, 98, 193
DNA methylation 59, 137, 140, 142, 174
DNA repair 50, 55, 154, 271
DNA replication 13, 56, 80, 125, 193, 225, 226
DNA synthesis 25, 26, 27, 102, 119, 120, 227, 234, 249
Docking 252, 254, 255
Dose-limiting toxicities (DLTs) 199, 201, 205
Doxorubicin 12, 13, 14, 22, 77, 98, 101, 115, 194, 215, 222
Drug design 4, 71, 72, 83, 120, 125, 227, 233, 250, 251
Drug development 24, 82, 87, 90, 159, 169, 196, 197, 198, 208, 218
Drug resistance 89, 90, 91, 107, 108, 154, 169, 170, 171, 172, 175, 176, 178, 181, 215
DNA methyltransferases (DNMTs) 58, 178, 180

E

Efflux pumps 40, 169, 170, 178, 179, 181, 236
Electrochemical 146, 148
Electronic structure 6, 256
Enzyme inhibition 25, 35, 77, 79, 98, 108, 193, 220
Enzyme inhibitors 176, 226, 227
Epigenetics 58, 91, 137, 174
Epithelial-mesenchymal transition (EMT) 80, 174, 175, 207, 224
Erlotinib 11, 32, 81, 117, 149, 151, 152, 174, 178, 228, 230
Evaluation 87, 191, 200, 208
Exosomes 136, 137, 141, 142, 146, 147, 158, 206, 207
Excretion 26, 40, 115, 143, 198, 203, 234, 236
Epidermal growth factor receptor (EGFR) 25, 52, 55, 81, 89, 119, 124, 142, 145, 149, 156, 228, 230

F

Flavonoids 53, 117, 122, 180, 217, 220, 221, 225
Free radicals 205, 221
Furan 2, 3, 4, 5, 8, 9, 219, 249
Functional groups 25, 87, 117, 153
Fibroblast growth factors (FGFs) 55

G

Gefitinib 11, 25, 32, 74, 81, 83, 89, 149, 153, 228, 230
Gene silencing 59, 140
Genetic mutations 23, 89, 90, 169, 171, 172, 216, 236
Genomics 197, 246
Genotoxicity 194, 195, 197, 198, 204
Green chemistry 15, 70, 71, 85, 143, 246, 252, 253, 259
Green synthesis 232, 239, 255
Glutathione-S-transferase (GST) 171, 173, 181

H

Hedgehog signaling pathway 26, 29
Heteroatoms 2, 4, 5, 6, 7, 9, 25, 26, 71, 72, 115, 143, 217, 269, 270
Heterogeneity 175, 215
Histone acetylation 59, 230
Histone modifications 59, 140, 142
Histones 79, 140, 174, 230
Hydrogen bonding 5, 77, 78, 130, 219, 269
Histone deacetylases (HDACs) 59, 60, 79, 80, 140, 143, 150, 174, 177, 180, 230

I

Ibrutinib 74, 127, 280, 282
Imatinib 11, 13, 14, 81, 83, 138, 140, 151, 152, 175, 218, 219, 234, 254, 255
Imidazoles 1, 4, 5, 6, 8, 9, 10, 25, 26, 37, 38, 40, 52, 53, 227
Immune responses 107, 114, 175, 176, 195, 221, 222, 234, 281, 282, 283
Immune system 23, 89, 151, 155, 195, 207, 282

Immunotherapies 15, 40, 50, 59, 207, 208, 246, 268, 281, 282, 283
Indoles 11, 14, 26, 33, 40, 74, 80, 84, 222, 225, 270, 271
Inflammation 25, 105, 106, 216, 217, 221, 222, 225, 229, 239
Intercalation 12, 30, 75, 78, 80
Intermolecular forces 130
Irinotecan 25, 30, 75, 125, 173, 194, 218, 225
Isoquinolines 26, 75, 179, 228

K

Kinases 11, 48, 50, 51, 81, 82, 83, 250, 251, 253, 255

L

Letrozole 38, 75, 76, 150
Lipophilicity 5, 22, 40, 77, 217, 284
Liposomes 90, 154, 177, 206, 207, 253, 277, 284
Liquid biopsies 138, 140, 145, 146, 147, 158
Long non-coding RNA (lncRNAs) 60, 61, 156
Lymphomas 14, 30, 33, 99, 125, 216, 224

M

Machine learning 15, 90, 156, 157, 159, 160, 234, 238, 239, 258
Malignancies 14, 53, 56, 57, 60, 102, 176, 183, 216, 281
Mechanistic target of rapamycin (mTOR) 49, 52, 55, 222, 231
Metabolic stability 4, 15, 71, 74, 79, 84, 218, 251, 252
Metabolism 50, 51, 143, 195, 196, 198, 203, 229, 234, 236
Metalloproteinases 82, 224
Metastasis 23, 24, 48, 49, 50, 53, 54, 79, 80, 81, 223, 224, 283
Methotrexate 14, 22, 25, 174, 215, 218, 234, 277
MicroRNAs (miRNAs) 60, 61
Microtubules 13, 224, 250, 253, 272
Mitochondrial dysfunction 194, 195, 208, 222
Mutagenicity 195, 235
Mutations 22, 23, 145, 148, 151, 171, 173, 174, 175, 193, 194, 256, 257, 276

Matrix metalloproteinases (MMPs) 79, 80, 223
Multidrug resistance (MDR) 90, 116, 171, 172, 173

N

Nanocarriers 90, 205, 206, 276
Nanoformulations 277, 279
Nanoparticles 90, 146, 154, 182, 251, 255, 258, 279, 280
Nanotechnology 70, 90, 91, 146, 155, 156, 252, 253, 256, 258, 268
Natural products 85, 87, 114, 116, 117, 119, 120, 122, 217, 218, 219
Nephrotoxicity 14, 106, 199, 200
Neurotoxicity 106, 195, 199, 272
Nitrogen 1, 2, 3, 4, 71, 72, 73, 74, 76, 77, 120, 130, 219, 248, 273
Nucleotides 27, 191, 219
Non-homologous end joining (NHEJ) 56

O

Off-target effects 40, 154, 237, 256
Oncogenic pathways 140, 251, 282
Organic compounds 48, 116, 143, 217, 224, 225, 248
Oxidative stress 25, 55, 180, 194, 195, 196, 205, 208, 216, 221, 225
Oxygen 1, 2, 3, 4, 72, 73, 76, 77, 130, 169, 170, 219, 223, 248, 273
Oxygen heterocycles 122, 180
Organic light-emitting diodes (OLEDs) 15, 256

P

Paclitaxel 13, 123, 222, 272
Parameters 198, 202, 203
Pharmacodynamics 143, 203, 253, 276, 284
Pharmacokinetics 89, 198, 199, 203, 235, 236, 251, 253, 255, 258, 276, 277, 284
Pharmacophores 1, 36, 82, 83, 192
Phosphorylation 103, 229
Piperidine 6, 8, 219, 271
Plasticity 175, 249, 250
Polarity 4, 10, 22, 26, 115, 284
Polymerase 50, 56, 79, 257
Polyphenols 205, 217, 221

Subject Index

Preclinical studies 87, 198, 200, 234
Prodrugs 83, 103, 179, 180, 181
Proliferation 48, 52, 58, 118, 123, 124, 194,
196, 227, 230, 272, 274
Proteins 37, 39, 55, 57, 120, 121, 141, 142,
146, 147, 194, 195, 219, 228, 229
Proteomics 197, 199, 259
Purines 4, 11, 25, 26, 27, 52, 108, 218, 227,
249, 270
Pyrazoles 25, 34, 48, 52, 53, 54, 71, 117, 226
Pyridines 1, 2, 4, 5, 6, 7, 8, 9, 29, 30, 74, 102,
219, 226, 228
Pyrimidines 13, 25, 26, 27, 52, 74, 82, 177,
178, 249, 270
Pyrroles 1, 2, 6, 7, 9, 146, 148, 219, 249
Poly(ADP-ribose) polymerase (PARP) 39, 50,
56, 81, 121, 257
Phosphoinositide 3-kinase (PI3K) 49, 55, 174,
222, 231
Proteolysis targeting chimeras (PROTACs)
251, 257
Prostate-specific antigen (PSA) 137, 141, 142,
146

Q

Quinazolines 10, 11, 15, 32, 52, 55, 81, 83,
149, 151, 228, 279, 281
Quinolines 1, 2, 4, 26, 30, 31, 75, 81, 84, 176,
178, 179, 221, 222
Quinolones 40, 48, 177, 226, 251
Quantitative structure-activity relationship
(QSAR) 83, 233, 239, 252

R

Radiation 23, 40, 50, 55, 56, 70, 216, 221
Radiation therapy 193, 246
Reactants 9, 10, 86
Reactions 2, 6, 8, 9, 10, 84, 85, 86, 87, 232,
233
Reactive intermediates 195, 220
Reagents 9, 86, 232
Receptors 9, 25, 26, 40, 118, 119, 124, 141,
142, 143, 144, 145, 215, 233, 251
Regorafenib 29, 81, 126, 279
Renal cell carcinoma 30, 99, 127, 230, 231
Reproductive toxicity 198, 236
RNA 99, 103, 117, 192, 218

Prediction in Medicine 295

Reactive oxygen species (ROS) 12, 124, 180,
194, 283
Receptor tyrosine kinases (RTKs) 33, 124,
230, 231

S

Scaffolds 11, 14, 61, 72, 73, 79, 80, 81, 82,
246, 249, 250, 252, 254, 268
Selectivity 78, 79, 82, 83, 84, 87, 88, 91, 229,
237, 251, 256, 257, 258
Sensors 15, 146, 148
Signalling pathways 199, 228
Signaling pathways 48, 54, 60, 61, 119, 149,
253, 274
Solvents 10, 231, 232, 233
Sorafenib 29, 81, 83, 115, 178, 223
Species 203, 221
Specificity 8, 50, 141, 147, 196, 202, 207,
217, 222, 276, 277
Stability 6, 8, 25, 84, 107, 117, 136, 137, 153,
278, 281
Substances 6, 11, 12, 15, 16, 31, 53, 54, 55,
56, 57, 269, 273, 278, 282
Substituents 8, 78, 269
Substitution 7, 9, 28
Sulfur 1, 176, 270, 274
Sunitinib 33, 74, 75, 80, 117, 144, 152, 154,
178, 223, 230
Synthesis 10, 70, 71, 72, 229, 231, 232, 233,
252, 253, 256, 257, 258
Synthetic lethality 57, 151
Structure-activity relationship (SAR) 40, 70,
71, 82, 83, 84, 233, 237, 252

T

Techniques 85, 148, 157, 182, 197
Tetrahydrofuran (THF) 8, 278, 281
Thiazoles 3, 4, 35, 76, 77, 179, 180, 220, 221,
227, 253, 255, 274
Thiazolidinone 180, 181, 278, 279, 280, 281
Thiophenes 2, 3, 4, 5, 6, 9, 78, 181, 220, 228,
249
Thrombocytopenia 199, 201
Tissues 106, 147, 181, 193, 223, 224, 229,
235, 236, 283
Topoisomerases 11, 12, 30, 75, 78, 80, 120,
121, 124, 125, 225, 226
Toxicity assessment 196, 198

Toxicokinetics 203, 204
Transcription 12, 13, 25, 53, 61, 77, 78, 194
Transcriptomics 199
Transformations 23, 86, 87, 220
Triazoles 10, 26, 38, 39, 40, 48, 75, 170, 222, 226, 227
Tubulin 82, 125, 224
Tumor growth 36, 52, 83, 223, 226, 249, 273, 279, 280, 282
Tumor microenvironment (TME) 50, 155, 160, 170, 174, 175, 176, 181, 182, 207, 282
Tumors 105, 106, 108, 140, 141, 145, 146, 149, 150, 151, 155, 206, 223, 276, 283
Tyrosine kinases 37, 50, 52, 57, 117, 149, 152, 160, 223, 229, 230
Tyrosine kinase inhibitors (TKIs) 11, 52, 151, 154, 173, 223, 227, 229, 230, 255, 256

V

Validation 256
Vascular endothelial growth factor (VEGF) 34, 54, 79, 223
Vinblastine 22, 33, 74, 125, 215, 271, 277
Vincristine 14, 22, 33, 74, 173, 174, 215, 224, 225, 271, 277
Vorinostat 59, 117, 140, 150, 152
Vascular endothelial growth factor receptor (VEGFR) 36, 80, 81, 117, 150, 223, 230, 250, 253

W

Waste production 233
Water solubility 3

X

Xenobiotics 196
Xenografts 89

Z

Zinc ion 82



Smriti Dewangan

Dr. Smriti Dewangan is an Associate Professor at Amity Institute of pharmacy, Amity University Chhattisgarh, Raipur, Chhattisgarh, India. With 12 years of teaching and research experience in Organometallic Chemistry at both undergraduate and postgraduate levels, she completed her PhD in Chemistry at the National Institute of Technology, Rourkela, Odisha, under an Institute MHRD Fellowship. She holds an M. Pharm in Pharmaceutics, funded by a GPAT fellowship, and was a gold medalist in her B. Pharm program. In 2019, she was honored with the Young Scientist Award by ISCA. Dr. Dewangan has authored numerous research papers, review articles, abstracts, book chapters, and books, published with leading academic publishers. She is also a life member of several professional societies.



Anchal Verma

Anchal Verma is an accomplished academic professional with over 13 years of experience as an Assistant Professor. She holds an M.Pharm degree in Pharmacology and is currently pursuing her Ph.D. She is associated with the Shri Rawatpura Sarkar Institute of Pharmacy, Kumhari, Chhattisgarh, India. Her expertise spans a wide array of fields, including molecular docking, synthetic chemistry, diabetes mellitus, Alzheimer's disease, and anti-inflammatory activity. She has contributed significantly to the academic community by publishing numerous research and review papers in reputed peer-reviewed journals. Additionally, she has mentored more than 15 undergraduate and postgraduate students, fostering the next generation of researchers and professionals.



Varsha Rawat

Ms. Varsha Rawat is a research scholar in Chhattisgarh Swami Vivekananda Technical University, Bhilai, Chhattisgarh, India. She is pursuing her PhD from Chhattisgarh Swami Vivekananda Technical University, Bhilai, Chhattisgarh. She is a pharmaceutical researcher and educator specializing in nanotechnology, drug development and herbal formulations. Her research focuses on the development of novel drug delivery systems, including curcumin-based nanoparticles for atherosclerosis. She has contributed to multiple peer-reviewed publications, book chapters and patents. With expertise in Nanotechnology cardiovascular drug development and herbal drug technology, she is committed to advancing pharmaceutical research and education.